PDFs of posters accepted for HIV Glasgow Congress 2024 are available below. Where there is not a hyperlink to a poster, we are awaiting confirmation from the presenter/submitter that they wish to include a PDF of their poster. The site will be updated as and when approvals are received.
ARV-based prevention – Vertical transmission ARV-based prevention – PEP ARV-based prevention – PrEP Treatment strategies – Novel therapeutic targets (phase I and II) Treatment strategies – RCTs: Oral and injectable therapy in first line and suppressed switch populations Treatment strategies – Real-world and implementation science studies oral and injectable therapy Treatment strategies – Treatment experienced adults (second-line and multi-drug resistance studies) Treatment strategies – Models of care for ageing/frail populations including virological failure and switching Treatment strategies – Rapid ART initiation Treatment Strategies – Adherence Clinical management considerations – Women Clinical management considerations – Late presenters Clinical management considerations – People who inject drugs (PWID) Clinical management considerations – Transgender people Clinical management considerations – Adolescents Clinical management considerations – Paediatrics Clinical management considerations – Drug-drug interactions Cure/post-treatment control Opportunistic infections and AIDS defining cancers Clinical pharmacology Community-based treatment and prevention initiatives, including primary care screening Public health strategies including of policy options Cost and cost-effectiveness Models of care: evaluation of ARV delivery and coverage Co-morbidities and complications of disease and/or treatment – Ageing and frailty Co-morbidities and complications of disease and/or treatment – Cardiovascular/metabolic including weight gain Co-morbidities and complications of disease and/or treatment – Malignancies: non-AIDS defining Co-morbidities and complications of disease and/or treatment – Neurological Co-morbidities and complications of disease and/or treatment – Renal Co-morbidities and complications of disease and/or treatment – Mental health disorders Co-morbidities and complications of disease and/or treatment – Other People living with HIV and COVID-19: Outcomes People living with HIV and mpox virus People living with HIV and sexually transmitted diseases People living with HIV and tuberculosis People living with HIV and viral hepatitis People living with HIV and other diseasesARV-based prevention – Vertical transmission
P001: Postnatal prophylaxis among infants born to women living with HIV in England, 2018-2022
Emily Dema, Rebecca Sconza, Helen Peters, Alasdair Bamford, Hermione Lyall, Kate Francis, Claire Thorne (London, UK) PDF
P002: Outcomes following prenatal exposure to DTG-containing antiretroviral therapy regimens:
data from the DOLOMITE-EPPICC study
Rebecca Sconza, Georgina Fernandes, Heather Bailey, Karoline Aebi-Popp, Luminita Ene, Marco Floridia, Anna Maria Gamell, Marta Illán Ramos, Helen Peters, Anna Samarina, Leigh Ragone, Vani Vannappagari, Claire Thorne (London, UK) PDF
P003: Antiretroviral therapy in pregnancy in England in 2019-2022: common regimens and treatment modifications
Rebecca Sconza, Helen Peters, Laurette L Bukasa, Laura Byrne, Alasdair Bamford, Hermione Lyall, Graham P. Taylor, Claire Thorne (London, UK) PDF
P004: HIV treatment cascade among pregnant women with pre-conception diagnosis: 2017-2022
Helen Peters, Rebecca Sconza, Kate Francis, Laura Byrne, Claire Thorne (London, UK) PDF
P005: The peripartum viral load cascade and outcomes of infants exposed to HIV in Lesotho
Kathrin Haenggi, Moleboheng Mokebe, Lipontso Motaboli, Makobefo Chakela, Mpho Kao, Mathebe Kopo, Irene Ayakaka, Monrongoe Nyakane, Tapiwa Tarumbiswa, Niklaus Daniel Labhardt, Jennifer Anne Brown, Nadine Tschumi (Basel, Switzerland) PDF
P006: Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT
Carmela Pinnetti, Cristina Marelli, Alice Ranzani, Valentina Mazzotta, Lucia Taramasso, Oscar Cirioni, Andrea Costantini, Barbara Menzaghi, Rosa Fontana Del Vecchio, Enrico Girardi, Annalisa Saracino, Antonella Cingolani, Antonio Di Biagio, Antonella d’Arminio Monforte, Andrea Antinori (Rome, Italy) PDF
P007: The experience of pregnancy in women living with HIV (WLWH) between 2000 and 2023:
a single-centre retrospective observational analysis
Sara Giovanna De Maria, Raffaella Marocco, Alessandra Grimaldi, Sara Corazza, Andrea Gasperin, Paola Zuccalà, Cosmo Del Borgo, Valeria Belvisi, Tiziana Tieghi, Miriam Lichtner (Rome, Italy) PDF
P008: A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG)
use during pregnancy: data from DOLOMITE-NEAT ID Network study
Justyna Kowalska, Sergii Antoniak, Lambert Assoumou, Anton Pozniak, Tetiana Rybak, Stephane De Wit, Ana Milinkovic, Sherie Roedling, Carl Fletcher, Leigh Ragone, Claire Thorne, Vani Vannappagari (Warsaw, Poland) PDF
ARV-based prevention – PEP
P009: Management of reported side effects to PrEP: high rates of retention on PrEP after switching to a different F/TDF generic brand
Nicolo Girometti, Frances Lander, Elizabeth Ridsdill Smith, Hasan Mirza, Sheena McCormack, Victoria Tittle (London, UK) PDF
P010: Analysis of occupational accidents involving exposure to biological fluids in a Portuguese peripheral hospital: implementation and efficacy of post-exposure prophylaxis
Clara Batista, Rita Pinto, Frederico Duarte, Ricardo Correia de Abreu, Sofia Jordão (Porto, Portugal) PDF
ARV-based prevention – PrEP
P011: Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre-exposure prophylaxis in Europe: the PrEPaRe study
Valentina Cambiano, Tina Bruun, Marie Louise Jakobsen, Ann Sullivan, Andrew Phillips (Copenhagen, Denmark) PDF
P012: PrEP cascade improvement through same-day PrEP initiation
Kevin Woodward, Timothy Guimond, Hommood Alrowais, Victor Monroy, Olivia Gemmell (Hamilton, Canada) PDF
P013: HIV-1 prevalence and pre-exposure prophylaxis uptake among key populations in high-income economies (2017-2023): a systematic review and meta-analysis of real-world studies
Li Tao, Xiwen Huang, Juan Yang, Jesse Najarro Cermeño, Soodi Navadeh, Julianna Catania, Kylie Scott, Sophie Schoeni, Dylan Mezzio (Foster City, CA, USA) PDF
P014: Preparing for long-acting PrEP delivery: provider preferences for the provision of long-acting PrEP differ between MSM and heterosexual individuals in Europe
Hanne Zimmermann, Haoyi Wang, Johann Kolstee, Alejandro Adriaque Lozano, Melanie Schroeder, Ama Appiah, Ana Milinkovic, Supriya Sakar, Kai Jonas (Maastricht, Netherlands)
P015: Intention to use long-acting PrEP among 4960 heterosexual women and men in 20 European countries: results from the PROTECT survey
Kai Jonas, Haoyi Wang, Hanne Zimmermann, Alejandro Adriaque Lozano, Melanie Schroeder, Ama Appiah, Ana Milinkovic, Supriya Sakar, Johann Kolstee (Maastricht, Netherlands) PDF
P016: Low uptake of mpox and HPV vaccination among PrEP users in Switzerland
Benjamin Hampel, Andrea Farnham, Celine Capelli, Enos Bernasconi, Dominique L. Braun, Alexandra Calmy, Julia Notter, Marcel Stoeckle, Bernard Surial, Vanessa Christinet, Katharine E. A. Darling, Manuela Rasi, Claudia Bernardini, David Haerry, Florian Vock, Nicola Low, Jan S. Fehr (Zurich, Switzerland) PDF
P017: Recurrence of sexually transmitted infections is commonly found in a sub-population of Austrian PrEP users
Nikolaus Urban, Thomas Neidhart, Katharina Grabmeier-Pfistershammer, Kaspar Laurenz Schmidt, Veronique Touzeau-Roemer, Nathalie Judith Auer, Robert Strassl, Wolfgang Weninger, Birgit Willinger, Wolfgang Michael Bauer, David Chromy (Vienna, Austria) PDF
P018: Effects of bariatric surgery on intracellular tenofovir-diphosphate levels in patients taking HIV
pre-exposure prophylaxis
Matthew McGarrity, Paul MacPherson, Abby Li, Mark Naccarato, Peter Anderson, Darrell Tan (Toronto, Canada) PDF
P019: Barriers and facilitators to pre-exposure prophylaxis (PrEP) uptake in England: experiences of people newly diagnosed with recently acquired HIV
Carina Hoerst, Hannah Kitt, Dolores Mullen, Helen Corkin, Clare Humphreys, Ammi Shah, Vicky Gilbert, Adamma Aghaizu (London, UK) PDF
P020: Changing unmet HIV PrEP need among men who have sex with men in London: an analysis of community cross-sectional surveys prior to and following routine HIV PrEP implementation in England
Flavien Coukan, Dana Ogaz, Gary Murphy, Hamish Mohammed, John Saunders, Fiona Burns (London, UK) PDF
P021: Chlamydia trachomatis serovars involved in lymphogranuloma venereum infections of men who have sex with men (MSM) and transgender women (TGW) in Buenos Aires, Argentina
Luciana Spadaccini, Martin Vacchino, Maria Ines Figueroa, Gissella Mernies, Agustin Nava, Carolina Perez, Diego Salusso, Maria Victoria Iannantuono, Jonathan Garcia, Carina Cesar, Valeria Fink, Zulma Ortiz, Patricia Galarza, Pedro Cahn (Buenos Aires, Argentina) PDF
P022: HIV pre-exposure prophylaxis (PrEP) failures in a large observational cohort from Poland with expansion of A6 subtype transmissions
Bartosz Szetela, Karol Serwin, Aleksander Zinczuk, Lukasz Lapinski, Aleksandra Szymczak, Kamila Zielinska, Mateusz Bozejko, Anna Urbanska, Jacek Gasiorowski, Milosz Parczewski (Wroclaw, Poland) PDF
P023: Addressing the unmet HIV prevention needs of women who have migrated from sub-Saharan Africa in France: an urgent call for PrEP integration in family planning centres
Victoria Manda, Julie Castaneda, Jean Guilleminot, Fati Abdou, Samantha Devlin, Eleanor Friedman, Jessica P. Ridgway, Amy K. Johnson, Geoffroy Liegeon (Paris, France)
P024: Determinants of loss to follow-up among pre-exposure prophylaxis users at a Portuguese tertiary hospital
Sara Magalhães, Sara Lino, Raquel Pinto, Maria Carlos, Gonçalo Cristóvão, Ana Catarina Gonçalves, João Caria, Vasco Almeida, Claudina Cruz, Marta Leal Santos, Diogo Bento, Stepanka Betkova, Raquel Garrote, Freddy Ramirez, Diana Póvoas, Diana Seixas, Orlando Cardoso, Maria José Manata, Fernando Maltez (Lisboa, Portugal) PDF
P025: Evolution from an HIV PrEP clinic to a comprehensive sexual health service in a tertiary university hospital in southeast Asia
Dariusz Olszyna, Tiane Le, Sophia Archuleta (Singapore, Singapore) PDF
P026: HIV incident infections in a PrEP cohort
Isabel Pastor, Guillermo Alberto Viloria, Mariana Angelica Kundro, Marina Alonso Serena, Maria Belen Zorz, Federico Cardozo, Marcelo Horacio Losso (Buenos Aires, Argentina) PDF
P027: Prevalence of the use of sports supplements and illicit drugs for use in gyms in people included
in HIV pre-exposure prophylaxis programmes (Gym-PrEP cohort)
Raquel Muñoz-Andrés, Sara de la Fuente Moral, Natalia Vicente-López, Ilduara Pintos-Ramos, Alberto Diaz de Santiago (Madrid, Spain) PDF
P028: Injectable PrEP is here, who wants it? Early lessons learned from injectable cabotegravir rollout
in Zambia
Daniel Mwamba (Lusaka, Zambia)
P029: PrEP-associated stigma in Europe: findings from a real-world survey
Melanie Schroeder, Fritha Hennessy, Libby Turner, Tim Holbrook, Ama Appiah, Jenny Scherzer (Munich, Germany) PDF
P030: Implementation of PrEP in Italy: results of PrIDE survey
Silvia Nozza, Valentina Mazzotta, Thomas Masoero, Alessandro Tavelli, Filippo Leserri, Lucia Taramasso, Daniele Tesoro, Enrico Tesoro, Antonella d’Arminio Monforte, Francesco Maria Fusco, Marianna Menozzi, Eugenio Milano, Davide Moschese, Roberto Rossotti, Francesco Barbaro, Salvio Cecere, Maddalena Giglia, Serena Venturelli, Massimo Cernuschi, Antonella Castagna, Andrea Antinori (Milano, Italy) PDF
P031: Dynamics of STIs during and after the COVID-19 pandemic in PrEP-cohort at the University Medical Center Hamburg-Eppendorf (UKE)
Nils Janis Steinhaus, Maher Almahfoud, Lukas Weimann, Hanna Matthews, Philine Diekhoff, Selina Pollich, Sabine Jordan, Till Koch, Guido Schaefer, Anja-Dorothee Huefner, Stefan Schmiedel, Julian Schulze zur Wiesch, Olaf Degen (Hamburg, Germany) PDF
P032: Does tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis induce changes in kidney function in people older than 50 years old?
Francisco Novela, Flávia Faria, Ema Pos, Soraia Almeida, Ana Cipriano, Josefina Mendez (Porto, Portugal) PDF
P033: There are still myths and misconceptions about it!! Assessing pre-exposure prophylaxis knowledge among adolescents in Zambia, a mixed method survey
Yvonne Kumwimba (Lusaka, Zambia)
P034: Clinical landscape of sexually transmitted infections among PrEP users: insights from a district hospital
Clara Bacelar, Fábio Reis, Eduarda Pena, Sara Araújo, Clara Batista, Ricardo Correia de Abreu, Frederico Duarte (Matosinhos, Portugal) PDF
Treatment strategies – Novel therapeutic targets (phase I and II)
P035: Pharmacokinetic/pharmacodynamic and resistance analyses of GS-1720, a once-weekly oral integrase strand transfer inhibitor
Brie Falkard, Haeyoung Zhang, Mutaz Jaber, Eva Mortensen, Furong Wang, Christian Callebaut, Dhananjay D. Marathe (Foster City, CA, USA) PDF Audio
P036: Effect of acid-reducing agents on the pharmacokinetics of oral GS-4182
Naveed Shaik, Sean Regan, Deqing Xiao, Furong Wang, Jason Hindman, Ramesh Palaparthy (Foster City, CA, USA) PDF
P037: Correlation of baseline phenotypic sensitivity with virological response to VH3810109 (N6LS) in BANNER
Margaret Gartland, Peter Leone, Judah Abberbock, Kathryn Brown, Paul Wannamaker, Rulan Griesel, Viviana Wilches, Jan Losos (Durham, NC, USA) PDF Audio
P038: Polyphenol-rich Camu Camu capsules effect on weight and liver markers in people living with HIV
on antiretroviral therapy: results of the Camu Camu pilot study (CTN PT 032)
Stephane Isnard, Léna Royston, Tsoarello Mabanga, Carolina A. Berini, Amélie Pagliuzza, Talat Bessissow, Peter L. Lakatos, Thibault Varin, Emendez Salazar, Taiki Hakozaki, Bertrand Lebouché, Cecilia T. Costiniuk, Giada Sebastiani, Marina Klein, Nicolas Chomont, Bertrand Routy, André Marette, Jean-Pierre Routy (Montreal, Canada)
P039: Geno2pheno-bNAbs: interpretable and accurate prediction of HIV-1 bNAb resistance
Martin Pirkl, Michael Boehm, Joachim Buech, Philipp Schommers, Florian Klein, Rolf Kaiser, Thomas Lengauer (Cologne, Germany) PDF
Treatment strategies – RCTs: Oral and injectable therapy in first line and suppressed switch populations
P040: Similar virological outcomes and frequency of isolated viraemic events (blips, low-level viraemia
and suspected virological failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir + rilpivirine long-acting studies
John Thornhill, Louise Garside, Chinyere Okoli, Patricia de los Rios, Kimberley Brown, Lori A. Gordon, Christine L. Latham, William Spreen (Brentford, UK) PDF Audio
P041: Doravirine plus raltegravir (DOR/RAL) two-drug regimen (2-DR) as a maintenance antiretroviral therapy in virally suppressed people living with HIV (PLWH): results of the international randomized DORAL trial
Romain Palich, Antonella Castagna, Clotilde Allavena, Andrea Antinori, Diana Canetti, Juan Tiraboschi, Claudine Duvivier, Esteban Martinez, Pere Domingo, Salima Barkat, Yasmine Dudoit, Lydie Beniguel, Gilles Peytavin, Cathia Soulié, Anne-Geneviève Marcelin, Lambert Assoumou, Christine Katlama (Paris, France) PDF
P042: Viral blips in the doravirine phase III clinical trials DRIVE-FORWARD and DRIVE-AHEAD
Jean-Michel Molina, Chloe Orkin, Roger Paredes, Zhi Jin Xu, Feng-Hsiu Su, Ernest Asante-Appiah, Rebeca M. Plank, Rima Lahoulou (Paris, France) PDF Audio
P043: Long-term efficacy and safety of dolutegravir/lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial – GESIDA 11820
Maria de Lagarde Sebastian, Rosa de Miguel Buckley, Jose Luis Blanco-Arevalo, Adriana Pinto, Rocio Montejano Sanchez, Angela Gutiérrez Liarte, Roser Navarro-Soler, Esperanza Cañas Ruano, Alexy Inciarte, Luz Martin-Carbonero, Arkaitz Imaz, Cristina Hernandez Gutierrez, Antonio Ocampo Hermida, Marta de Miguel, Rafael Delgado Vazquez, Federico Pulido Ortega, Jose Ramon Arribas Lopez (Madrid, Spain) PDF Video
P044: Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomised D2ARLING study
Ezequiel Cordova, Jeniffer Hernandez Rendon, Veronica Mingrone, Patricio Martin, Gisela Arevalo Calderon, Soledad Seleme, Jamile Ballivian, Norma Porteiro (Buenos Aires, Argentina) PDF
P047: An EYEWITNESS to successful diversity in antiretroviral switch studies
Cornelius Van Dam, Maria Jose Crusells-Canales, Bliss Leverette, Mounir Ait-Khaled, Emilio Letang, Alex Pitchford, Richard Grove, Riya Moodley, Karen Anderson, Deanna Merrill, Miguel Pascual-Bernaldez, V. Paul DiMondi, Bryn Jones (Durham, NC, USA) PDF
P048: Changes in patient-reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO-DOBLE randomized clinical trial
Lucio Garcia-Fraile, Mar Masia, Maria J. Crusells-Canales, Pere Domingo, Adria Curran, Roberto Guerri-Fernandez, Enrique Bernal, Joaquin Bravo, Boris Revollo, Juan Macias, Juan M. Tiraboschi, Rocio Montejano Sanchez, Concepcion Amador, Miguel Torralba, Dolores Merino, Vicens Diaz-Brito, Maria J. Galindo Puerto, Sergio Ferra, Aroa Villoslada, Juan E. Losa, Francisco J. Fanjul, Javier Perez-Stachowski, Joaquim Peraire, Joaquin Portilla, Sara de la Fuente Moral, Carlos Dueñas, Maria J. Vazquez, Silvana Di Gregorio, Eduardo Manzanares, Pedro Gil, Marta de Miguel, Jose Luis Blanco-Arevalo, Pablo Ryan, Belen Alejos, Esteban Martinez (Barcelona, Spain) PDF
P049: Pharmacokinetic (PK) analysis of oral once-daily bictegravir (BIC) plus lenacapavir (LEN) administered separately (BIC 75 mg + LEN 25 mg; BIC 75 mg + LEN 50 mg) and as BIC/LEN 75/50 mg single-tablet regimen to support phase III dose selection
Priyanka Arora, Elise Oh, Jairo M. Montezuma-Rusca, Peter Sklar, Deqing Xiao, Nieves Velez de Mendizabal, Ramesh Palaparthy, Dhananjay D. Marathe (Foster City, CA, USA) PDF
P050: Metabolic changes at 48 weeks in virologically suppressed people with HIV switching from complex antiretroviral regimens to bictegravir plus lenacapavir: ARTISTRY-1 trial
David Prelutsky, Karam Mounzer, Moti Ramgopal, Jihad Slim, Malcolm Hedgcock, Sorana Segal-Maurer, Mark Bloch, Xu Zhang, Jairo M. Montezuma-Rusca, Peter Sklar, Peter Ruane (Foster City, CA, USA)
P051: Comparison of treatment-emergent resistance associated mutations among single tablet regimens and cabotegravir+rilpivirine for the treatment of virologically suppressed people with HIV:
a systematic literature review and network meta-analysis
Ishfaq Rashid, Teerapon Dhippayom, Connor Willis, Howard Weston Schmutz, Moti Ramgopal, Elizabeth Sherman, Rachel Safran, Nicholas Yared, Amy R. Weinberg, Soodi Navadeh, Nathan R. Unger, Nathorn Chaiyakunapruk (Fort Pierce, FL, USA) PDF
P053: Predictive efficacy of dual therapy combining integrase strand transfer inhibitors with second-generation non-nucleoside reverse transcriptase inhibitors following HIV-1 treatment failure in Cameroon: potential implications for the use of long-acting therapeutic strategy in low- and middle-income countries
Davy Hyacinthe Gouissi Anguechia, Yagai Bouba, Ezechiel Ngoufack Jagni Semengue, Desire Takou, Aude Ka’e, Collins Ambe Chenwi, Grace Beloumou, Alexis Ndjolo, Nicaise Ndembi, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam (Yaounde, Cameroon)
P054: RUMBA’s week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF
Sophie Degroote, Evy Blomme, Liesbeth Delesie, Linos Vandekerckhove, Marie-Angélique De Scheerder (Ghent, Belgium) PDF Video
Treatment strategies – Real-world and implementation science studies oral and injectable therapy
P056: Real world outcomes of cabotegravir and rilpivirine for treating PLHIV in Spain: a multicentre, ambispective and nationwide study (the RELATIVITY cohort)
Luis Buzon Martin, Montes Maria Luisa, Maria J. Galindo Puerto, Miguel Torralba González, Guillermo Pousada, Mireia Santacreu, Ignacio de los Santos, Alfonso Cabello Úbeda, Noemi Cabello Clotet, María José Crusells-Canales, Luis Enrique Morano, Patricia Martin Rico, Carmen Montero Hernández, Alberto Diaz de Santiago, Álvaro Cecilio, Miguel Alberto de Zárraga Fernández, Enrique Bernal, María Antonia Sepúlveda, María Jesús Vivancos Gallego, Roberto Pedrero Tomé, Mar Masiá Canuto, Ruth Calderón Hernáiz, Cristina Diez Romero, Juan Emilio Losa García, Manuel Gutiérrez Cuadra, Jara Llenas-García, Ana Cerezales Calviño, Antonio Sánchez Guirao, Josefa Soler González, Miriam Estébanez, Beatriz de la Calle Riaguas, María Ángeles Garcinuño Jiménez, Maria del M. García Navarro, Noemi Ramos Vicente, Marta Clavero Olmos, Miguel Egido Murciano, Eva Ferreira Pasos, Jesús Troya García (Burgos, Spain) PDF
P057: Antiretroviral treatment in PLWH with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: a real-world cohort analysis
Gundolf Schuettfort, Alfonso Cabello, Maria Crusells-Canales, Miguel Gorgolas Hernández-Mora, Carmen Hidalgo-Tenorio, Juan Lopez, Rafael Mican, Roser Navarro-Soler, Eugenia Negredo, Sebastian Noe, Jordi Puig, Jürgen Rockstroh, Sergio Rodriguez, Rosario Serrao, Christoph Stephan, Miguel Torralba, Diva Trigo, Maria Vivancos, Annette Haberl (Frankfurt, Germany) PDF
P058: Long acting cabotegravir plus lenacapavir as a fully injectable maintenance antiretroviral regimen in people with HIV with adherence issues
Romain Palich, Romain Manchon, Jérémy Zeggagh, Elisabete Gomes-Pires, Sophie Seang, Marc-Antoine Valantin, Marc Wirden, Marianne Burgard, Gilles Peytavin, Claudine Duvivier (Paris, France) PDF
P059: Real-world experience of DTG+3TC regimen: results from the French Dat’AIDS cohort (2015-2022)
Clotilde Allavena, Romain Palich, Alain Makinson, Amélie Ménard, David Rey, Laetitia Roustand, Corinne Vouillot, Laurent Hocqueloux (Nantes, France) PDF
P060: Feasibility, acceptability and effectiveness of long acting injectable antiretrovirals in the “Acceptability and Feasibility of long-acting INjectable ART in Adolescents and Young Adults (AFINAty)” study in South Africa
Lauren Jennings, Millicent Atujuna, Chantel Schreuder, Nyiko Mashele, Metsekae Madimabe, Linda-Gail Bekker, Catherine Orrell (Cape Town, South Africa PDF
P061: Durability of doravirine containing regimens in people with HIV in real-life settings in the ANRS CO3 cohort: AQUIVIH-NA
Olivier Leleux, Alaric Peyrouny-Mazeau, Adélaïde Perrier, Mojgan Hessamfar, Gwenaël Le Moal, Didier Neau, Laure Alleman, Charles Cazanave, Estibaliz Lazaro, Pierre Duffau, Agnés Riché, Yann Gérard, Marie-Anne Vandenhende, Fabrice Bonnet (Bordeaux, France) PDF
P062: Re-suppression regimens and outcomes after virological failure in randomized controlled trials and real-world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV)
Alexa Elias, Melanie Smuk, Kyle Ring, Chloe Orkin (London, UK) PDF
P063: Four-year outcomes from the BICSTaR study: observational analysis of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV in Canada, France, and Germany
Alex Wong, Daniel Beer, Claudine Duvivier, Hugues Cordel, Anja Meurer, David Thorpe, Marion Heinzkill, Andrea Marongiu, Johanna Ramroth, Benoit Trottier (Saskatchewan, Canada) PDF
P064: Long-acting injectable cabotegravir and rilpivirine outcomes in HIV-positive migrants in Spain: do they have worse outcomes?
Jara Llenas-García, Roberto Pedrero Tome, Luis Ramos Ruperto, María José Galindo Puerto, Mariano Matarranz del Amo, Carolina Navarro, Miguel Torralba, Gutiérrez Lara, María Aguilera García, Alfonso Cabello Úbeda, Isabel San Joaquín Conde, Luis Enrique Morano, Noemí Cabello-Clotet, Patricia Martín Rico, Carmen Montero Hernández, Elisa Pino, Alberto Díaz de Santiago, Ruth Calderón Hernaiz, Enrique Bernal, María Jesús Vivancos Gallego, María Antonia Sepúlveda, Chiara Fanciulli, Álvaro Cecilio, Josefa Soler González, Sergio Padilla, Juan Emilio Losa García, Carlos Armiñanzas Castillo, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, María Ángeles Garcinuño Jiménez, Eva Ferreira Pasos, Miriam Estébanez, Beatriz de la Calle Riaguas, Teresa Omiste Sanvicente, Noemí Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, Ana Lucas Dato, on behalf of the RELATIVITY Multicentre Cohort (Orihuela, Spain) PDF
P065: Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: a substudy of the RELATIVITY cohort
Maria Jose Galindo Puerto, Noemí Cabello Clotet, Teresa Aldamiz-Echevarría Lois, Jara Llenas García, Mari Mar Arcos, Jesús Troya, Luis Buzón Martín, Miguel Torralba, Mireia Santacreu, Maria Aguilera García, Alfonso Cabello Úbeda, Maria Jose Crusells-Canales, Luis Morano, Roberto Pedrero Tomé, Patricia Martin Rico, Carmen Montero Hernández, Desiree Perez Martinez, Sara de la Fuente Moral, Ruth Calderón Hernáiz, Enrique Bernal, María Jesus Vivancos Gallego, Maria Antonia Sepúlveda, Alvaro Cecilio, Víctor Arenas García, Sergio Padilla, Juan Emilio Losa García, Francisco Arnaiz de las Revillas Almajano, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, Maria Angeles Garcinuño Jiménez, Eva Maria Ferreira Pasos, Miriam Estebanez, Beatriz De la Calle Riaguas, Miguel Egido Murciano, Noemí Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, on behalf of the RELATIVITY Multicentre Cohort (Valencia, Spain) PDF
P066: Causes of discontinuation of long-acting cabotegravir and rilpivirine in clinical practice: results from the prospective multicentre SCOLTA cohort
Lucia Taramasso, Nicola Squillace, Elena Ricci, Sergio Ferrara, Giancarlo Orofino, Eleonora Sarchi, Emanuele Pontali, Giovanni Cenderello, Giovanni Francesco Pellicanò, Filippo Lagi, Elena Salomoni, Olivia Bargiacchi, Maria Aurora Carleo, Luigi Pusterla, Salvatore Martini, Rita Bellagamba, Giordano Madeddu, Giuseppe Vittorio De Socio, Barbara Menzaghi, Goffredo Angioni, Katia Falasca, Antonio Cascio, Antonio Di Biagio, Paolo Bonfanti (Monza, Italy) PDF
P067: Treatment patterns in virologically suppressed, treatment-experienced people with HIV: a US real-world database study
Samir Gupta, Katherine Cappell, Kwanza Price, Machaon Bonafede, Joshua Gruber, JeanPierre Coaquira Castro, Soodi Navadeh, Robert Sedgley, Sorana Segal-Maurer (Foster City, CA, USA) PDF
P068: Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence
Marta Boffito, Jason Brunetta, Itzchak Levy, Chia-Jui Yang, Joaquín Portilla, Eoghan De Barra, Roger Vogelmann, Tomoyuki Endo, Olivier Robineau, Loredana Sarmati, David Thorpe, Andrea Marongiu, Tali Cassidy, Berend van Welzen (London, UK) PDF
P069: Long-acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients
Ana Moreno, Santos Del Campo, Maria Jesus Perez-Elias, Jose Luis Casado, Miguel Garcia, Manuel Velez, Maria Jesus Vivancos, Santiago Moreno (Madrid, Spain) PDF
P071: Switching from integrase strand transfer inhibitors (INSTIs) based triple therapy to dual therapy in people with HIV-1 infection (PWH): the French hospital database on HIV (ANRS CO4 FHDH) real-life experience
Emilie Lanoy, Claudine Duvivier, Nathalie De Castro, Sophie Abgrall, Sylvie Bregigeon-Ronot, Fabienne Caby, Colin Deschanvres, Jade Ghosn, Marina Karmochkine, Christine Katlama, Odile Launay, Christian Pradier, Jacques Reynes, Dominique Salmon, Dominique Costagliola, Sophie Grabar (Paris, France) PDF
P072: Central nervous system safety of long-acting cabotegravir/rilpivirine in patients with previous oral INSTI-related CNS toxicity
Ana Moreno, Santos Del Campo, Maria Jesus Vivancos, Manuel Velez, Jose Luis Casado, Javier Martinez, Fernando Dronda, Santiago Moreno, Maria Jesus Perez-Elias (Madrid, Spain) PDF
P073: DTG/3TC as initial therapy in people living with HIV and viral load >500,000 copies/mL
Juan Martin, Maria Lagarde, Judit Iglesias, David Rial, Otilia Bisbal-Pardo, Adriana Pinto, Roser Navarro, Mireia Santacreu, Maria Teresa Lopez, Laura Bermejo Plaza, Maria Asuncion Hernando, Rafael Rubio, Federico Pulido Ortega (Madrid, Spain) PDF
P074: Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort
Giada Canavesi, Maurizio Mena, Elena Zaninetta, Lidia Gazzola, Teresa Bini, Giancarlo Orofino, Andrea De Vito, Giordano Madeddu, Chiara Grillo, Claudia Bartalucci, Federica Centorrino, Nicola Squillace, Paolo Bonfanti, Giorgio Tiecco, Emanuele Focà, Marianna Menozzi, Giovanni Guaraldi, Nicolas Brian Bana, Giovanni Cavazza, Roberto Rossotti, Sergio Lo Caputo, Antonio Di Biagio, Stefano Rusconi (Legnano, Italy) PDF
P075: Real-life effectiveness, safety and acceptance of long-acting cabotegravir-rilpivirine: results from a large single-centre cohort
Ana González-Cordón, Montserrat Laguno, Leire Berrocal, Maria Martínez-Rebollar, Berta Torres, Ivan Chivite, Alexy Inciarte, Paula Arreba, Juan Ambrosioni, Alberto Foncillas, Lorena de la Mora, José Luis Blanco-Arevalo, Júlia Calvo, Esteban Martinez, Abiu Sempere, Jose M. Miró, Roger Llobet, Elisa de Lazzari, Josep Mallolas (Barcelona, Spain) PDF
P076: Persistence, safety and virological outcomes of B/F/TAF as a baseline or switch regimen in HIV-infected people living with advanced HIV disease in the real world: the BIC-CD4 study
Diego Cecchini, Carla Serrano, Martín Brizuela, María Magdalena Puchulu, Gastón Copertari, Brenda Bacelar, Juan Manuel Nuñez, Juan Gonzalo Tomás, Romina Mauas, Macarena Roel, Edgardo Bottaro, Isabel Cassetti (Buenos Aires, Argentina) PDF
P077: Effectiveness of long-acting ART with cabotegravir/rilpivirine in the ICONA cohort
Roberta Gagliardini, Sara De Benedittis, Alessandro Tavelli, Giuseppe Lapadula, Valentina Mazzotta, Elena Bruzzesi, Adriana Cervo, Giorgia Carrozzo, Annalisa Sarracino, Stefano Rusconi, Giulia Marchetti, Francesca Ceccherini-Silberstein, Andrea Antinori, Antonella d’Arminio Monforte, Camilla Muccini (Milan, Italy) PDF
P078: Use of long-acting cabotegravir and rilpivirine in a real-life setting: 12-month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH-NA cohort-France
Mojgan Hessamfar, Olivier Leleux, Alaric Peyrouny-Mazeau, Camille Krzyzanowsky, Gwenaël Le Moal, Didier Neau, Hélène Ferrand, Arnaud Desclaux, Estibaliz Lazaro, Pierre Duffau, Yann Gérard, Marie-Anne Vandenhende, Fabrice Bonnet (Bordeaux, France) PDF
P079: Switching to LA CAB/RPV in virologically suppressed PLHIV: does knowing previous genotyping really matter? A substudy from the RELATIVITY cohort
Luis Buzon Martin, María Luisa Montes, María José Galindo Puerto, Miguel Torralba, Victoria Mancheño De Real, María Aguilera García, Alfonso Cabello Úbeda, Isabel San Joaquín Conde, Luis Morano, Noemi Cabello Clotet, Patricia Martín Rico, Carmen Montero Hernández, Miguel Alberto de Zárraga Fernández, Sara de la Fuente Moral, Ruth Calderón Hernaiz, Enrique Bernal, María Jesús Vivancos Gallego, María Antonia Sepúlveda, Roberto Pedrero Tomé, Cristina Diez Romero, Álvaro Cecilio, Jara Llenas-García, Victor Arenas García, Mar Masiá Canuto, Juan Emilio Losa García, Carlos Armiñanzas Castillo, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, María Ángeles Garcinuño Jiménez, Eva Ferreira Pasos, Miriam Estébanez, Beatriz de la Calle Riaguas, Miguel Egido Murciano, Noemi Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, Jesús Troya (Burgos, Spain) PDF
P080: Prevalence of virological failure and resistance patterns to long-acting cabotegravir-rilpivirine: a real-life single-centre cohort study
Ana González-Cordón, Alexy Inciarte, Mar Mosquera, Leire Berrocal, Maria Martinez-Rebollar, Berta Torres, Ivan Chivite, Paula Arreba, Juan Ambrosioni, Alberto Foncillas, Lorena De La Mora, Julia Calvo, Abiu Sempere, Jose M. Miró, Roger Llobet, Elisa De Lazzari, Josep Mallolas, Esteban Martinez, Montserrat Laguno, Jose Luis Blanco-Arevalo (Barcelona, Spain) PDF
P081: Long-acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real-world study (RELATIVITY cohort)
Jesús Troya, Luis Morano, Jose Ignacio Bernardino, Luis Buzón Martin, Roberto Pedrero Tomé, María José Galindo Puerto, Miguel Torralba, Noemí Cabello Clotet, María García López, Silvia Lope, Miguel Alberto de Zárraga Fernández, Alfonso Cabello, María Aguilera García, Álvaro Cecilio, Alberto Díaz de Santiago, María Ángeles Garcinuño Jiménez, Enrique Bernal, María Teresa López Caballero, Ruth Calderón Hernaiz, María Jesús Vivancos Gallego, Teresa Omiste Sanvicente, Eva Ferreira Pasos, Juan Emilio Losa García, Josefa Francisca Soler González, María Antonia Sepulveda, María del Mar García Navarro, on behalf of the RELATIVITY Multicentre Cohort (Madrid, Spain) PDF
P082: CARAVEL: evaluation of real-world effectiveness and sustainability of the two-drug regimen dolutegravir/lamivudine fixed-dose combination in treatment-naive adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France: 2-year interim analysis results
Patrick Philibert, Charlotte Charpentier, Nilakshani Naguleswaran, Caroline Philippe, Laetitia Roustand, Corinne Vouillot, Laurent Hocqueloux (Marseille, France) PDF
P083: Incidence of comorbidities over 18 months with BIC/FTC/TAF, DTG/ABC/3TC or DTG/3TC in real-life settings in the ANRS-CO3-AquiVIH-NA cohort
Olivier Leleux, Alaric Peyrouny-Mazeau, Adélaïde Perrier, Mojgan Hessamfar, Gwenaël Le Moal, Didier Neau, Laure Alleman, Charles Cazanave, Estibaliz Lazaro, Pierre Duffau, Agnés Riché, Yann Gérard, Marie-Anne Vandenhende, Fabrice Bonnet (Bordeaux, France)
P084: Real-world utilization of cabotegravir + rilpivirine in Southern Spain: data from the CARIPLA study
Rosario Palacios, Cristina Gómez-Ayerbe, Marisa Mayorga, Nuria Espinosa, Alicia Hidalgo, Francisco Téllez, Ana Belén Lozano, Mónica Loring, Jesús Santos (Málaga, Spain) PDF
P085: HIV-2 chronic infection and BIC/FTC/TAF experience in a Portuguese tertiary hospital in Lisbon
Margarida Almeida, Constança Antunes, Mariana Pereira, Marta Almeida, Ana Cláudia Miranda, Kamal Mansinho (Lisboa, Portugal)
P086: Discontinuation of rilpivirine and cabotegravir in HIV-1 virologically suppressed adults: a multicentre observational study in Tuscany (LAHIV study)
Filippo Lagi, Giuseppe Formica, Massimiliano Fabbiani, Barbara Rossetti, Matteo Piccica, Susanna Giachè, Daniela Messeri, Silvia Costarelli, Erika Riguccini, Giovanni Sarteschi, Michele De Gennaro, Emanuela Francalanci, Giuseppe Gasparro, Marco Fognani, Riccardo Paggi, Paola Corsi, Marco Pozzi, Gaetana Sterrantino, Mario Tumbarello, Pierluigi Blanc, Filippo Bartalesi, Donatella Aquilini, Cesira Nencioni, Danilo Tacconi, Spartaco Sani, Antonella Vincenti, Alessandro Bartoloni (Florence, Italy) PDF
P087: Effectiveness and safety of BIC/FTC/TAF for late-presenting people with HIV-1 infection
Hai Long, Xiaoxin Xie, Xiaoyan Yang, Yanhua Fu, Lin Gan, Shujing Ma (Guiyang, China)
P088: Virological failure rate and emergent resistance in real-world studies evaluating long-acting cabotegravir and rilpivirine in people with baseline viral suppression
Melanie Smuk, Alexa Elias, Kyle Ring, Chloe Orkin (London, UK) PDF
P089: Profile of people with HIV (PWH) switching prior antiretroviral treatment (ART) to a doravirine
(DOR)-based regimen in the real-world clinical setting in Greece: the DORAVITO study
Antonios Papadopoulos, George Adamis, Panagiota Lourida, Vassileios Paparizos, Helen Sambatakou, Symeon Metallidis, Charalampos Moschopoulos, Myrto Astriti, Charisis Totsikas, Varvara Vasalou, Eleni Boutselakou, Dimitris Tsokos, Georgios Trimis, Lazaros Poughias (Athens, Greece) PDF
P090: PLWH treated with cabotegravir-rilpivirine have increased CD4/CD8 ratio and decreased CD8 T-cells, as expression of lower inflammation, while maintaining virological suppression: a real-life 48 weeks analysis
Giuseppe Nunnari, Serena Spampinato, Giuseppe Nicolo Conti, Carmen Giarratana, Teresa Cirelli, Viviana Coco, Michele Salvatore Paterno Raddusa, Viviana Fisicaro, Chiara Gullotta, Roberto Bruno, Eugenia Pistarà, Nunziatina Villari, Bruno Cacopardo, Emmanuele Venanzi Rullo, Andrea Marino, Benedetto Maurizio Celesia, Giovanni Pellicanò, Alessia Mirabile (Catania, Italy)
P091: Discontinuation rates of doravirine/lamivudine/tenofovir-DF due to neuropsychiatric adverse effects
Iresh Jayaweera, Rory Grier-Gavin, Rosy Weston, Nicola Mackie, Lucy Garvey, John Walsh, Alan Winston, Borja Mora-Peris (London, UK)
P092: Switch to dolutegravir/lamivudine in virologically suppressed people living with HIV: a real-world experience in a low-middle income country
Julian Vega, Micaela Sogga Alfano, María Clara Villaverde, Alejandra Mariaca, Diego Sanchez Thomas, José Ángel Enrique Barletta, María José Rolón, Gustavo Lopardo (Buenos Aires, Argentina)
P093: Effectiveness and safety of dual therapy with co-packed DTG and 3TC compared to triple therapy in clinical practice in Argentina
Edgardo Bottaro, Diego Cecchini, Brenda Bacelar, Angeles Tisné, Claudia Migazzi, Macarena Roel, Maximiliano Bergman, Isabel Cassetti (Buenos Aires, Argentina) PDF
P094: Two-year long-term data on the efficacy and tolerability of dolutegravir-based regimens from the prospective multi-centre TESLA cohort study in ART-naïve and pre-treated people living with HIV in Russia
Anna Basova, Stella Minaeva, Natalia Sizova, Firaya Nagimova, Elena Orlova-Morozova, Margarita Radzikhovskaya, Valeriy Shevchenko, Andrés Maldonado-Doblado, Bryn Jones (Moscow, Russian Federation) PDF Audio
P095: Demographic and clinical characteristics of treatment naïve people with HIV, and their healthcare professionals’ reasons for treatment choice: findings from a real-world survey in five European countries
Andrea Marongiu, Tali Cassidy, Joshua Gruber, Hannah Jones, Katherine Li, Will Ambler, Fritha Hennessy, Tim Holbrook (Uxbridge, UK) PDF
P096: Results at month 7 of CABO-CHANCE study: real-world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)
Carmen Hidalgo-Tenorio, María Aguilera-García, Ignacio De los Santos, David Vinuesa, Mohamed Omar, Ana Lopez Lirola, Enrique Bernal, Onofre Juan Martinez, Alberto Romero, Patricia Sorni, Teresa Lopez, Salvador López Cárdenas, Santiago Moreno, Isabel San Joaquín Conde, José Ramón Blanco, Coral Garcia-Vallecillos (Granada, Spain) PDF
P097: Efficacy and safety of long-acting cabotegravir + rilpivirine at All Saints Clinic in Wroclaw (Poland): real-life single-centre 2-year experience
Marzena Dawiec, Jacek Gasiorowski, Aleksandra Szymczak, Aleksander Zinczuk, Malgorzata Inglot, Brygida Knysz, Kamila Zielinska, Joanna Bortkiewicz, Michal Furdal, Mateusz Bozejko, Bartosz Szetela (Wroclaw, Poland) PDF
P098: Real-world persistence of bictegravir- versus dolutegravir-based single tablet regimens in a large urban Canadian HIV centre
David Knox, Jennifer McCully, Graham S. Smith, Negin Mousadifar, Angela Underhill, Taban Saifi, Dylana Mumm, Colin Kovacs, Jason Brunetta, William Tsang, Megan Acsai, Barry Merkley, Kevin Giolma, David Fletcher, Tali Cassidy, Soodi Navadeh, Mona Loutfy (Toronto, Canada) PDF
P099: Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long-acting (LA) CAB+RPV administration out of HIV units: the IMADART study
Alfonso Cabello, Irene Carrillo Acosta, Aws Al-Hayani, Marta López De Las Heras, Cristina Algar, Inmaculada Burillo, Beatriz Álvarez-Álvarez, Laura Prieto-Pérez, Ignacio Mahíllo-Fernández, Macarena Bonilla, Laura García, José Manuel Caraballo, Mónica Esparis, Beatriz Gallego, Javier Bécares, Miguel Górgolas Hernández-Mora (Madrid, Spain) PDF
P100: Long-term efficacy, safety and metabolic impact of generic dolutegravir in treatment-naïve and experienced people living with HIV: a real-world study in Argentina
Edgardo Bottaro, Angeles Tisne, Brenda Bacelar, Claudia Migazzi, Macarena Roel, Maximiliano Bergman, Diego Cecchini, Isabel Cassetti (Buenos Aires, Argentina) PDF
P101: PAIRED – PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States
Jihad Slim, Andrew P. Brogan, Gavin Harper, Katie Mycock, Abigail McMillan, Deanna Merrill, Gustavo Verdier (Montreal, Canada) PDF
P102: Factors influencing the prescription of long-acting injectable dual therapy cabotegravir/rilpivirine in a Northwest Paris region cohort
Jeremie Leporrier, Vincent Daneluzzi, Souhayla Amari, Ghania Bouteira, Séverine Dubois, Feng Zeng, Martine Bloch, Ghislaine Nguisseu, Elisabeth Aslangul (Colombes, France) PDF
P103: T-cell homeostasis parameters following switch to injectable cabotegravir plus rilpivirine in virally suppressed people living with HIV (PLWH)
Camilla Tincati, Leonardo Francesco Rezzonico, Andrea Santoro, Emanuela Ferrante, Teresa Bini, Lidia Gazzola, Giulia Marchetti (Milan, Italy) PDF
P104: Switching to long-acting intramuscular cabotegravir and rilpivirine in virologically suppressed PLHIV treated with dolutegravir/rilpivirine: a substudy from the RELATIVITY cohort
María José Galindo Puerto, Luis Buzón Martín, Jesús Troya, Luz Martin Carbonero, Laura Bermejo Plaza, Miguel Torralba, Carmen Montero Hernández, Miguel Alberto de Zárraga Fernández, Roberto Pedrero Tomé, Noemí Cabello Clotet, Víctor Arenas García, Javier García Abellán, Alfonso Cabello Úbeda, Juan Emilio Losa García, María José Crusells-Canales, Jara Llenas García, Beatriz De la Calle Riaguas, Luis Morano, Maria Aguilera García, Patricia Martin Rico, Enrique Bernal, Sara de la Fuente Moral, Ruth Calderón Hernáiz, María Antonia Sepúlveda, Marouane Menchi, Marta Clavero Olmos, Manuel Gutiérrez Cuadra, Miriam Estebanez, Barbara Alonso Moreno, Álvaro Cecilio, Miguel Egido Murciano, Guillermo Cuevas Tascón, on behalf of the RELATIVITY Multicentre Cohort (Valencia, Spain) PDF
P105: Real-world evidence of B/F/TAF in Chile: effectiveness and safety from the BIKUCH cohort
Alejandro Afani, Alba Rivas, Camila Maulen, Pedro Zitko (Santiago, Chile) PDF
P106: Antiretroviral treatment with BIC/FTC/TAF: where we come from and where we are going
Adrian Rodriguez, Aroa Villoslada, Patricia Sorni, Marta Molero, Antoni Adrover, Ana Andreu, Ana Liebana, Joaquin Serrano, Francisco Homar, Antoni Payeras (Palma, Spain) PDF
P107: Patient-reported outcomes in switching to long-acting cabotegravir/rilpivirine: a real-life experience
Anna Carraro, Raffaella Marocco, Giulia Mancarella, Paola Zuccalà, Lorenzo Ansaldo, Sara De Maria, Sara Corazza, Alessandra Grimaldi, Andrea Gasperin, Cosmo Del Borgo, Miriam Lichtner (Latina, Italy)
P108: The analysis of metabolic parameters in people living with HIV using dolutegravir-based regimens in routine clinical practice in Russia
Anna Basova, Stella Minaeva, Natalia Sizova, Firaya Nagimova, Elena Orlova-Morozova, Margarita Radzikhovskaya, Valeriy Shevchenko, Andrés Maldonado-Doblado, Bryn Jones (Moscow, Russian Federation) PDF Audio
P109: Switching from triple therapy to DTG/3TC in HIV-1 infected migrants without previous resistance test results
Frederico Duarte, Clara Bacelar, Eduarda Pena, Fábio Reis, Clara Batista, Susana Oliveira, Sofia Jordão, Maria João Gonçalves, Sónia Rocha, Cristina Soeiro, Ricardo Correia de Abreu (Matosinhos, Portugal) PDF
P110: Real-world experience with 3TC+DTG in low-resource setting in Latin America
Jimena Lopez Pineiro, Karla Bendezu Mejía, Juan Pablo Stagnaro (La Plata, Argentina) PDF Audio
P111: Treatment adherence and virological suppression in an outpatient cohort of people living with HIV (PLWH) on long-acting injectable HIV therapy
Catharina Dannenberg, Maher Almahfoud, Lukas Weimann, Hanna Matthews, Olaf Degen, Julian Schulze zur Wiesch (Hamburg, Germany)
P112: Therapy satisfaction and preference for injectable long-term options of Portuguese HIV patients: a multicentric case-study
Cristina Valente, Ruben Carvalho, Catia Caldas, Carmela Pineiro, Daniel Coutinho, Sofia Nunes, Sara Lino, Fernando Maltez, Raquel Pinho, Josefina Mendez, João Matos, Helder Pinheiro, Inês Vaz Pinto, Frederico Duarte, Ricardo Correia de Abreu, Ricardo Racha-Pacheco (Coimbra, Portugal) PDF
P113: T-cell homeostasis and microbial translocation in PLWH switching from triple to dual INSTI-based combination antiretroviral therapy (cART)
Valeria Bono, Camilla Tincati, Matteo Augello, Roberta Rovito, Sabrina Marozin, Andrea Santoro, Giulia Marchetti (Milan, Italy) PDF
P114: HIV-1 viral decay in blood and semen in antiretroviral-naive adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide
Ran Wang, Yongjian Liu, Lijun Sun, Aixin Li, Shiyun Lv, Yuanyi Zhai, Rui Li, Wei Hua, Xi Wang, Lin Li, lili Dai (Beijing, China) PDF
Treatment strategies – Treatment experienced adults (second-line and multi-drug resistance studies)
P115: Simplification of complex antiretroviral treatment regimens to two-class therapies in people with HIV
Christine Baumgartner, Dominique Laurent Braun, Huldrych Günthard, Roger Kouyos, Alexandra Calmy, Catia Marzolini, Matthias Cavassini, Enos Bernasconi, Patrick Schmid, Gilles Wandeler, Andri Rauch, Bernard Surial, Anna Hachfeld (Bern, Switzerland) PDF Video
P116: CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low-level viraemia (LLV) up to week 192 with fostemsavir (FTR)-based regimens in individuals with multidrug-resistant (MDR) HIV-1
Vincenzo Spagnuolo, Natalia Gregori, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Alftan Dyson, Manyu Prakash, Andrew Clark (Brentford, UK) PDF Audio
P117: Genotypic assessment of the viability of second-generation NNRTIs as an alternative therapy for ART-experienced individuals with multi-class HIV drug resistance in Botswana
Nokuthula Ndlovu, Ontlametse Choga, Wonderful Choga, Natasha Moraka, Dorcas Maruapula, Patrick Mokgethi, Kaelo Seatla, David Nkwe, Vlad Novitsky, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana) PDF
P118: High prevalence of HIV drug resistance among people living with HIV on dolutegravir-based antiretroviral therapy with viral load above 200 copies/mL in Francistown, Botswana
Ontlametse T. Choga, Goitseone M. Lemogang, Wonderful T. Choga, Gaonyadiwe Muzanywa, Thembinkosi M. Shadreck, Charity Ralegoreng, Dorcas Maruapula, Natasha O. Moraka, Catherine K. Koofhethile, Patrick T. Mokgethi, Kedumetse Seru, Boitumelo Zuze, Patience Montshosi, Irene Gobe, Modisa S. Motswaledi, Rosemary Musonda, Tony Chebani, Judith Nawa, Lindani Bochena, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana) PDF
P119: Replication-competent HIV-1 harbouring resistance-associated mutations is present in the viral reservoir
Michelle L. D’Antoni, Silvia Chang, Laurie A. VanderVeen, Christian Callebaut (Foster City, CA, USA) PDF
P120: Virological efficacy of dolutegravir plus darunavir in multi-drug-resistant HIV patients: a real-world cohort study with data from the PRESTIGIO registry
Filippo Lagi, Michele Bellomo, Riccardo Lolatto, Filippo Ducci, Seble Tekle Kiros, Rebecka Papaioannu, Tommaso Celemente, Leonardo Calza, Marcello Feasi, Emanuele Focà, Andrea Giacomelli, Roberto Gulminetti, Barbara Menzaghi, Antonella Castagna (Florence, Italy) PDF
P121: Effectiveness of switching to B/F/TAF in virologically suppressed people with HIV and with pre-existing resistance-associated mutations in Italy: the BIC-BARRIER study
Federico Conti, Laura Pezzati, Alessandro Cozzi-Lepri, William Gennari, Cristina Mussini, Emanuele Pontali, Anna Volpe, Ilaria Vicenti, Annalisa Saracino, Barbara Rossetti, Bianca Bruzzone, Adrian Shallvari, Laura Albini, Dario Corsini, Maurizio Zazzi, Stefano Rusconi (Lecco, Italy) PDF
P122: Switch from etravirine to doravirine as a part of antiretroviral combination in virally suppressed people living with HIV (PLWH): results of the French multicentre, observational SWEED study
Romain Palich, Jade Ghosn, Karine Lacombe, Christia Palacios, Pierre Delobel, Pascale Puglièse, Clotilde Allavena, Claudine Duvivier, Firouze Bani-Sadr, Olivier Robineau, Yasmine Dudoit, Duc Hoan, Aissata Kaba, Cathia Soulie, Christine Katlama, Lambert Assoumou (Paris, France) PDF
P123: Kinetics of non-nucleosidic reverse transcriptase (NNRT) resistance-associated mutations in HIV-1 blood reservoir in NNRTI-experienced people with HIV: the KINNDeR study
Thomas Drumel, Justine Sourice, Colin Deschanvres, Audrey Rodallec, Clotilde Allavena, François Raffi, Elisabeth Garnier (Nantes, France) PDF
P125: Efficacy and safety of dolutegravir (DTG)-based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): a single-arm clinical trial (DTG-SOT)
Jose M. Miró, Daniela Malano Barletta, Leire Berrocal, Christian Manzardo, Anna Castelli, Merce Brunet, Octavi Roman, Juan Ambrosioni, Frederic Cofan, Angela Gonzalez, Pablo Ruiz, Gonzalo Crespo, Alejandro Forner, Maria Angeles Castel, Montserrat Laguno, Montserrat Tuset, Elisa de Lazzari, Antonio Rimola, Asuncion Moreno (Barcelona, Spain) PDF
P126: Differentiating APOBEC- and drug-resistant populations by clonal analysis of near full-length proviral HIV-1 genome in highly treatment-experienced people living with HIV
Nina Engel, Axelander Thielen, Martin Däumer, Jens Verheyen, Roger Vogelmann (Mannheim, Germany) PDF
P127: Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®/BFTAF) in patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) mutations
Jane Akodu, Zoe Agyemang, Gavin Marshall, Alan Hunter, Pedro Simoes, Jennifer Hart, Fiona Burns, Tristan J. Barber (London, UK)
P128: Long-term durability of rilpivirine + darunavir/cobicistat dual regimen in antiretroviral-experienced people living with HIV (RilDaco study)
Diego Ripamonti, Laura Comi, Federica Borghi, Serena Venturelli, Daniela Valenti, Andrea Francavilla (Bergamo, Italy) PDF
P129: Long-term efficacy and safety of a maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate
Beatriz Borjabad, Alexy Inciarte, Ivan Chivite, Anna González-Cordon, Maria del Mar Mosquera, Berta Torres, Lorena De La Mora, Maria Martinez-Rebollar, Montserrat Laguno, Alberto Foncillas, Juan Ambrosioni, Josep Mallolas, Cristina Rovira, Carmen Hurtado, Abiu Sempere, Julia Calvo, Leire Berrocal, Jose M. Miró, Jose Alcamí, Jose Luis Blanco-Arevalo, Sonsoles Sanchez-Palomino, Elisa de Lazzari, Esteban Martinez (Sant Joan Despí, Spain) PDF
P130: Evaluation of HIV-DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under virological control: a longitudinal study from the PRESTIGIO registry
Daniele Armenia, Vincenzo Spagnuolo, Maria Concetta Bellocchi, Laura Galli, Greta Marchegiani, Tommaso Clemente, Luca Carioti, Riccardo Lolatto, Micol Ferrara, Roberta Gagliardini, Giulia Carla Marchetti, Carlo Torti, Giuseppe De Socio, Chiara Fornabaio, Maurizio Zazzi, Antonella Castagna, Maria Mercedes Santoro (Rome, Italy) PDF
P131: Low prevalence of protease inhibitor mutations among people living with HIV in Botswana: insights from the Botswana Combination Prevention Project
Marea Pema, Dorcas Maruapula, Doreen Ditshwanelo, Natasha Moraka, Nokuthula Ndlovu, Ontlametse Bareng, Patrick Mokgethi, Wonderful Choga, Boitumelo Zuze, Catherine Koofhethile, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana) PDF
P132: Three- versus two-drug doravirine-based regimens: a multicentre observational study
Adriana Cervo, Andrea Giacomelli, Roberto Rossotti, Marianna Menozzi, Beatrice Fontana, Elena Martini, Giacomo Menegotto, Maddalena Albertini, Andrea Rabbione, Maria Vittoria Cossu, Davide Moschese, Cristina Gervasoni, Giovanni Guaraldi (Modena, Italy) PDF
P133: No impact of the M184I/V mutation on the efficacy of tenofovir or abacavir+lamivudine+doravirine in HIV treatment-experienced people
Cathia Soulie, Aliou Baldé, Fofana Djeneba, Charlotte Charpentier, Pascale Bonnafous, Justine Sourice, Anne De Monte, Veronique Avettand-Fenoel, Helene Le Guillou-Guillemette, Laurence Bocket, Stephanie Raymond, Stephanie Marque Juillet, Mary-Anne Trabaud, Brigitte Montes, Anne Maillard, Cedric Hartard, Elodie Alessandri-Gradt, Etienne Brochot, Anne Signori-Schmuck, Lambert Assoumou, Anne-Genevieve Marcelin (Paris, France) PDF
P134: Salvage ART regimens based on a combination of an integrase inhibitor and doravirine in heavily antiretroviral-treated people living with HIV
Irina Ianache, Cristiana Costescu, Miruna Dragne, Gratiela Tardei, Roxana Radoi, Cristiana Oprea (Bucharest, Romania) PDF
P135: Similar efficacy, safety and CD4 T-cell increase up to week 96 observed with fostemsavir (FTR)-based regimens in the BRIGHTE study and dolutegravir (DTG)-based regimens in the VIKING-3 study in individuals with multidrug-resistant (MDR) HIV-1
Antonella Castagna, Natalia Gregori, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Alftan Dyson, Bryn Jones, Manyu Prakash, Andrew Clark (Milan, Italy) PDF Audio
P136: What is the current place for protease inhibitors in people living with HIV? A retrospective single-centre study
Ava Diarra, Agnes Meybeck, Vincent Derdour, Maxime Degrendel, Macha Tetart, Emmanuelle Aissi, Nathalie Viget, Laurence Bocket, Enagnon Kazali (Tourcoing, France) PDF Audio
P137: Real-life use of bictegravir/TAF/emtricitabine in a cohort of people with HIV with a high burden of comorbidities and a history of advanced HIV disease
Andrea De Vito, Giulia Moi, Giuseppe Conti, Benedetto Maurizio Celesia, Serena Spampinato, Andrea Marino, Claudia Calì, Maria Antonietta Di Rosolini, Laura Corda, Vincenzo Raimondo, Giovanna Sanna, Goffredo Angioni, Giuseppe Nunnari, Giordano Madeddu (Sassari, Italy)
P138: Bictegravir’s effect on persistent low level viraemia and immunological response. BELAIR study: a pilot prospective observational study
Vasileios Petrakis, Periklis Panagopoulos, Petros Rafailidis, Grigorios Trypsianis, Stavroula Zisaki, Dimitrios Papazoglou (Alexandroupolis, Greece) PDF
P139: HIV treatment with maraviroc: forgotten, not needed or still useful? Results from the MIRROR study
Andreas Müller, Markus Bickel, Eva Herrmann, Pavel Khaykin, Axel Müller, Gundolf Schuettfort, Christoph Stephan, Annette Haberl (Frankfurt am Main, Germany) PDF
P140: The virological efficacy of B/F/TAF in people living with HIV who experienced treatment failure: a real-world cohort
Min Yin, Ziqing Yuan (Fuyang, China) PDF
P141: Early treatment failure with lenacapavir in HIV-2 infection
Martin Obermeier, Özlem Yildirim, Robert Ehret, Maher Almahfoud, Dirk Berzow, Bernhard Krüdewagen, Olaf Degen (Berlin, Germany) PDF
P142: HIV GRADE drug resistance interpretation web tool update for capsid and post-attachment inhibitors
Martin Obermeier, Robert Ehret, Alexander Thielen, Martin Däumer, Björn Jensen, Carina Elsner, Christopher Dächert, Elena Knops, Eva Geringer, Eva Heger, Eva Wolf, Frank Wiesmann, Hauke Walter, Andrea Hauser, Christian Hoffmann, Irene Görzer, Jens Verheyen, Josef Eberle, Karin Metzner, Klaus Korn, Thomas Lengauer, Karolin Meixenberger, Martin Stürmer, Max Münchhoff, Patrick Braun, Stefan Esser, Thomas Klimkait, Rolf Kaiser, Nadine Lübke (Berlin, Germany) PDF
P143: Safety and efficacy of switch to ictegravir/emtricitabine/tenofovir alafenamide fumarate following dual regimen therapy in HIV: insights from the ICONA cohort
Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, Andrea Giacomelli, Roberto Rossotti, Giacomo Ponta, Nicoletta Bobbio, Alice Ianniello, Antonella Cingolani, Giordano Madeddu, Andrea Antinori, Antonella d’Arminio Monforte (Sassari, Italy)
Treatment strategies – Models of care for ageing/frail populations including virological failure and switching
P144: Safety and efficacy of doravirine plus tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in heavily pre-treated patients
Ana Moreno, Jose Luis Casado, Maria Jesus Vivancos, Isabel Izuzquiza, Manuel Velez, Fernando Dronda, Javier Martinez, Raquel Ron, Santos Del Campo, Santiago Moreno, Maria Jesus Perez-Elias (Madrid, Spain) PDF
P145: Safety and efficacy of dual doravirine plus lamivudine as a switch strategy in HIV patients with metabolic or renal issues
Ana Moreno, Jose Luis Casado, Manuel Velez, Maria Jesus Vivancos, Isabel Izuzquiza, Javier Martinez, Santos Del Campo, Santiago Moreno, Maria Jesus Perez-Elias (Madrid, Spain) PDF
P146: Switching to dual therapy in elderly and multi-experienced patients: profile of a reference service in Brazil
Luisa de Oliveira Pereira, Jorge Casseb, Mariana Monteiro, Ana Paula Rocha Veiga, Najara Ataide de Lima Nascimento, Luisa Caracik de Camargo (São Paulo, Brazil) PDF
Treatment strategies – Rapid ART initiation
P147: Impact of NGS-detected viral mutations on HIV viral decay in patients initiating a BIC/TAF/FTC regimen
Marcello Trizzino, Roberta Gaudiano, Luca Pipitò, Celestino Bonura, Claudia Gioè, Benedetta Romanin, Irene Ganci, Dalila Mimì Arena, Antonio Cascio (Palermo, Italy) PDF
P148: Synthesising HIV clinical guidelines on characteristics, challenges and facilitators of rapid initiation of antiretroviral therapy: a rapid scoping review
Moustafa Laymouna, Kim Engler, Dominic Chu, Nicholas Hickens, Tibor Schuster, Joel Ishak, Alexandra De Pokomandy, Bertrand Lebouché (Montreal, Canada) PDF
P149: Temporal trends from HIV diagnosis to ART initiation among adults living with HIV in the Asia-Pacific (2013-2023)
Thinh Vu, Dhanushi Rupasinghe, Vohith Khol, Romanee Chaiwarith, Junko Tanuma, Nagalingeswaran Kumarasamy, Suwimon Khusuwan, I. Ketut Agus Somia, Sanjay Pujari, Man Po Lee, Rohidas T. Borse, Sasisopin Kiertiburanakul, Evy Yunihastuti, Iskandar Azwa, Jun Yong Choi, Hsin-Pai Chen, Rossana Ditangco, Anchalee Avihingsanon, Yasmin Gani, Jeremy Ross, Awachana Jiamsakul (New York, NY, USA) PDF
P150: HIV-1 infection recency and pre-treatment drug resistance in recently diagnosed individuals in Greater Gaborone, Botswana: a cross-sectional insight to the “Treat All” strategy
Natasha Onalenna Moraka, Marea Neo Pema, Goitseone Martha Lemogang, Charity Ralegoreng, Thembinkosi Milili Shadrack, Patrick Mokgethi, Doreen Ditshwanelo, Segomotso Maphorisa, Modiegi Bridget Mothudi, Wonderful Tatenda Choga, Ontlametse Thato Bareng, Dorcas Maruapula, Terence Mohammed, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana) PDF
P151: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: a sub-study of the BIC-NOW clinical trial
Sergio Sequera-Arquelladas, Maria J. Vivancos, David Vinuesa, Antonio Collado, Ignacio De los Santos, Patricia Sorni, Noemi Cabello-Clotet, Marta Montero, Carlos Ramos-Font, Alberto Terrón, Maria J. Galindo Puerto, Onofre Juan Martínez, Pablo Ryan, Mohamed Omar, Helena Albendin-Iglesias, Rosario Javier, Miguel A. López-Ruz, Alberto Romero, Coral García-Vallecillos, Miguel A. Calleja, Carmen Hidalgo-Tenorio (Granada, Spain) PDF
P152: Multicentre, prospective cohort study of same-day initiation of antiretroviral therapy with BIC/FTC/TAF among antiretroviral-naïve people with HIV
Yi-Chia Huang, Hsin-Yun Sun, Po-Liang Lu, Po-Lin Chen, Nan-Yao Lee, Sung-Hsi Huang, Chien-Yu Cheng, Shu-Hsing Cheng, Chia-Jui Yang, Hung-Jen Tang, Shih-Ping Lin, Bo-Huang Liou, Yuan-Ti Lee, Chien-Ching Hung (Hsinchu County, Taiwan) PDF
P153: Examining the rapid initiation of B/F/TAF strategy through a Canadian lens: an HIV transmission modelling approach
Kimberly Guinan, Karine Mathurin, Bertrand Lebouché, Jean Lachaine (Montreal, Canada) PDF
P154: Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with HIV-1 (PWH): a systematic literature review (SLR) of clinical and patient-reported outcomes (PROs)
Jade Ghosn, Jeremy Chow, Monica Gandhi, Miguel Górgolas Hernández-Mora, Aws Al-Hayani, Hansel Tookes, Max Lee, Emily Kaiser, David Molebranche, Fernando Bognar, Bhumi Gandhi-Patel, Lilli Dai (Paris, France) PDF
P155: Same-day initiation with bictegravir/emtricitabine/tenofovir alafenamide: real-life experience from a centralized single-centre model of care for people living with HIV in Croatia
Josip Begovac, Iva Lisicar, Vanja Romih Pintar, Sime Zekan (Zagreb, Croatia) PDF
P156: Effectiveness and safety of rapid initiating with BIC/FTC/TAF regimen in advanced people with HIV: a real-world study from southwest of China (EVIDENCE study)
Yingchun Zhu, Lin Cai, Yin Wang, Buyun Wang (Chengdu, China)
P157: Rapid initiation of antiretroviral therapy under the Treat-All policy reduces loss to follow-up and virological failure in routine HIV care settings in China: a retrospective cohort study (2016-2022)
Huan Xia, Ping Ma (Tianjin, China)
P158: Rapid start: evaluating the time to HIV therapy initiation in a tertiary care hospital in Portugal (2020-2023)
Tiago Neves, Mariana Lopes, Helena Alves, Cristina Valente (Coimbra, Portugal) PDF Audio
P159: Effectiveness and safety analysis of B/F/TAF for rapid initiation of therapy in people with HIV
Yuanhong He, Lin Liu, Tongtong Yang, Jinghong Li, Dianxia Cheng, Ruifeng Zhou (Chengdu, China) PDF
Treatment Strategies – Adherence
P160: Real-world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support programme in Canada, preliminary results
Callahan LaForty, Adenike Adelakun, Ryan Ng, Bo Chen, Maria Esther Perez Trejo, Lidija Latifovic, Simbarashe Mhishi, Joann Ban (Mississauga, Canada) PDF Audio
P161: Effectiveness of enhanced adherence counselling among adolescents receiving dolutegravir-containing regimens with detectable viraemia in Cameroon: optimizing virological outcomes in paediatric settings
Suzie Moyo Tetang, Yagai Bouba, Alex Durand Nka, Aude Christelle Ka’e, Rachel Kamgaing, Davy Hyacinthe Gouissi Anguechia, Nelly Kamgaing, Michel Carlos Tommo Tchouaket, Nadine Nguendjoung Fainguem, Annie Nga Motaze, Francis Ateba, Desire Takou, Lum Forgwei, Dominik Guebiapsi Tameza, Cynthia Ayafor, Efakika Gabisa Jeremiah, Michelle A. Abate, Felicite Noukayo, Suzanne Essamba, Alice Ketchaji, Liman Yakouba, Ezechiel Ngoufack Jagni Semengue, Basseck Roland Wome, Agabus Wiadamong, Abdou Gnambi, Etame Naomi-Karell, Aurelie Minelle Kengni Ngueko, Larissa Moko, Junie Flore Yimga, Collins Ambe Chenwi, Grace Beloumou, Sandrine Djupsa, Rita Ekwoge Mejane, Samuel Martin Sosso, Rogers A. Ajeh, Abdelkader Bacha, Patrice Tchendjou, Anne Esther Njom Nlend, Paul Koki Ndombo, Daniele Armenia, Vittorio Colizzi, Francesca Ceccherini-Silberstein, Maria Mercedes Santoro, Alexis Ndjolo, Carlo-Federico Perno, Joseph Fokam (Yaounde, Cameroon)
P162: Factors associated with lost to follow-up (LTFU) on TB treatment at a large volume clinic in Kampala, Uganda
Lyness Bitira, Mark Muhumuza, Prisca Mwanga, Patrick Kazooba (Kampala, Uganda) PDF
P163: Global survey to evaluate engagement in care and treatment experiences of people with HIV
Xavier Guillaume, Robin Barkins, Marcel Dams, Nomfundo Eland, Maureen Owino, Carlos Saucedo, Yun-Chung Lu, Amina Omri, Alissar Moussallem, Larkin Callaghan, Michael Bogart, Connie Kim, Megan Dunbar (Foster City, CA, USA) PDF
P164: Exploring the minimal proportion of days covered (PDC) threshold required for achieving 90% viral suppression in people with HIV in the era of single-tablet regimens
Chun-Yuan Lee, Tien-Heng Ku, Yi-Pei Lin, Chia-Yu Tsai, Po-Liang Lu (Kaohsiung City, Taiwan) PDF
P165: Physician attitudes towards anti-retroviral therapy adherence and unmet treatment needs in people with HIV: a real-world survey in Europe and the United States
Rebecca Charlton, Will Ambler, Mark Small, Tim Holbrook, Fritha Hennessy (Bollington, UK) PDF
P166: Exploring latent adherence profiles in South African people living with HIV using group-based trajectory modelling
Campbell McDuling, Lauren Jennings, Christopher Ferraris, Paul D’Avanzo, Robert H. Remien, Catherine Orrell, Francesca Little (Cape Town, South Africa) PDF
P167: Effectiveness of mobile health technology in improving HIV care continuity and service delivery among sex workers in Sex Workers Outreach Project (SWOP) clinics, Kenya
Idah Mirera, Maureen Akolo (Nairobi, Kenya) PDF
P168: Health-related quality of life among the people living with HIV in Armenia
Tatevik Balayan (Yerevan, Armenia)
P169: Determinants of treatment interruptions in tuberculosis patients at Reach Out Mbuya: insights from a 3-year retrospective study
Damalie Nakyomu, Patrick Kazooba, Gertrude Namale, Emmanuel Sendaula, Josephine Kaleebi (Kampala, Uganda) PDF
Clinical management considerations – Women
P170: HIV infection in migrant women from sub-Saharan Africa in North East of Italy: a snapshot of a vulnerable population
Anna Ferrari, Lolita Sasset, Marco Cola, Claudia Cozzolino, Maria Cristina Rossi, Fabio Rigo, Veronica Del Punta, Angela Londero, Massimiliano Lanzafame, Sandro Panese, Marina Malena, Vinicio Manfrin, Annamaria Cattelan (Padua, Italy) PDF
P171: Women living with HIV: how far to fulfil the gap?
Adriana Cervo, Mariachiara Pellegrino, Federica Casari, Cinzia Puzzolante, Giovanni Guaraldi, Cristina Mussini (Modena, Italy) PDF
P172: Postpartum care pathway of women living with HIV in the North of France from 2011 to 2021
Noémie Lemee, Agnès Meybeck, Roxane Vanspranghels Gibert, Maxime Degrendel, Pauline Coulon, Olivier Robineau, Pauline Thill (Tourcoing, France) PDF
P173: CONception to Child-Rearing in the Early Treatment Era (CONCRETE): a qualitative study of the experiences of women living with HIV during pregnancy and motherhood
Clara Merlin, Clara Le Saux, Nelly Courvoisier, Jose Damas, Katharine Darling (Lausanne, Switzerland) PDF
P174: Managing menopause in women living with HIV: impact of online medical education on physician knowledge and confidence
Shanthi Voorn, Alessia Piazza, Gill Adair, Elizabeth Bukusi, Susan Cole-Haley, Shema Tariq (London, UK) PDF
P175: Contraceptive methods in women living with HIV after a pregnancy: Condesa’s Clinics, Mexico City
Teresita Cabrera, Marla Toiber, Edgar Pérez, Carlos Nava, Ubaldo Ramos, Ana Karen Soto, Elena Langarica, Adrian Cruz, Paula Viveros, Andrea Gónzalez (Ciudad de México, Mexico) PDF
P176: Prevalence and determinants of HIV sero-positivity among vulnerable older women in rural Uganda: a call for targeted policy interventions
Gertrude Ddamulira Namale, Emmanuel Sendaula, Hilda Achayo, Silas Masari, Patrick Kazooba, Josephine Kaleebi (Kampala, Uganda)
Clinical management considerations – Late presenters
P177: Effectiveness of dolutegravir and boosted-darunavir three-drug regimens in advanced ART naive: a trial emulation
Roberta Gagliardini, Andrea Giacomelli, Cristina Mussini, Stephen R. Cole, Jessie K. Edwards, Carmela Pinnetti, Alessandro Raimondi, Spinello Antinori, Silvia Nozza, Valentina Mazzotta, Giulia Marchetti, Sergio Lo Caputo, Andrea Antinori, Alessandro Cozzi-Lepri (Rome, Italy) PDF
P178: Risk of long-term clinical progression in PWH initiating a first-line ART with advanced HIV disease and failing to have a robust CD4 count response despite viral suppression
Giulia Marchetti, Camilla Tincati, Alessandro Cozzi-Lepri, Valeria Bono, Alessandro Tavelli, Eugenio Milano, Stefania Piconi, Cecilia Costa, Annalisa Mondi, Andrea Gori, Miriam Lichtner, Andrea Antinori, Francesca Ceccherini-Silberstein, Antonella d’Arminio Monforte, Carlo-Federico Perno (Milan, Italy) PDF
P179: Screening characteristics of participants in an open label, multi-centre, randomized controlled trial investigating integrase inhibitor versus boosted protease inhibitor antiretroviral therapy for late presenters with advanced HIV disease (LAPTOP)
Georg Behrens, Lambert Assoumou, Jose Arribas, Christine Katlama, Frank Post, Jean Michel Molina, Andrea Antinori, Rafael Micán, Stephane De Wit, Jürgen Rockstroh, Lisa Hamzah, Pere Domingo, Adrian Curran, Montserrat Laguno, Carl Fletcher, Debbie Roberts, Jack Moody, Anton Pozniak, Study Group LAPTOP (Hannover, Germany) PDF
P180: Late presentation and HIV-1 subtype diversity among Ukrainian migrants newly diagnosed with HIV in Poland
Milosz Parczewski, Iwona Cielniak, Ewa Siwak, Elżbieta Mularska, Adam Witor, Błażej Rozpłochowski, Bogusz Aksak-Was, Magdalena Witak-Jedra, Aleksandra Szymczak, Bartosz Szetela, Monika Bociąga Jasik, Anna Kalinowska-Nowak, Paweł Jakubowski, Maria Hlebowicz, Elzbieta Jablonowska, Wladysław Łojewski, Anita Olczak, Kaja Mielczak, Piotr Zabek (Szczecin, Poland) PDF
P181: HIV late presentation and advanced HIV disease increased in Latin America during second year of the COVID-19 pandemic
María Marta Greco, Pedro Zitko, Carlos Beltrán, Ernesto Martínez Buitrago, Alejandro Afani, Jesús Elías Dawaher, Andrea González, Isabel Cassetti, Mónica Mantilla, Ana Lucía Tobias, Elena Obieta (La Plata, Argentina)
P182: Implementation of HIV teams sustainably improves HIV indicator condition testing rates in hospitals in the Netherlands: the #aware.hiv study
Carlijn Jordans, Klaske Vliegenthart-Jongbloed, Kara Osbak, Jaap Hanssen, Marion Vriesde, Jan van Beek, Natasja van Holten, Willemien Dorama, Dorien van der Sluis, Annelies Verbon, Anna Roukens, Casper Rokx (Rotterdam, Netherlands) PDF
P183: Late HIV diagnosis in a cohort from Buenos Aires: high mortality and burden of HIV-related disease during the first year
Ana Rodriguez, Victoria Pinto, Julián Vega, Violeta Zulema Ortiz, José Ángel Enrique Barletta, María José Rolón (Ciudad Autónoma de Buenos Aires, Argentina) PDF
P184: Assessing the burden of advanced HIV disease among newly diagnosed individuals in three high-volume facilities in Kampala, Uganda: a retrospective study (2021-2023)
Julia Linda Ainemukama, Wycliff Sekayi, Patrick Kazooba, Gertrude Namale, Emmanuel Sendaula, Josephine Kaleebi (Kampala, Uganda) PDF
P185: Late HIV diagnosis in low- and middle-income countries (LMIC): opportunities and challenges ahead
Victoria Pinto, Ana Rodriguez, José Ángel Enrique Barletta, Julián Vega, Violeta Zulema Ortiz, Maria José Rolón (Ciudad Autónoma de Buenos Aires, Argentina) PDF
Clinical management considerations – People who inject drugs (PWID)
P186: Exploring potential interactions between intramuscular cabotegravir (CAB)/rilpivirine (RPV) and methadone: a case report
Pierluigi Francesco Salvo, Gianmaria Baldin, Valentina Iannone, Elena Visconti, Simona Di Giambenedetto (Rome, Italy) PDF
P187: The community pop-up clinic (CPC): HIV treatment in vulnerable population of people who use drugs
David Truong, Shana Yi, Christina Wiesman, Brian Conway (Vancouver, Canada) PDF
P188: Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy
David Truong, Shana Yi, Christina Wiesman, Brian Conway (Vancouver, Canada PDF
Clinical management considerations – Transgender people
P189: Transforming HIV care: intramuscular bimonthly cabotegravir and rilpivirine for transgender people with HIV in Spain (RELATIVITY cohort)
Alberto Díaz de Santiago, Pablo Ryan-Murua, María José Crusells-Canales, Luis Buzón Martin, Patricia Martín-Rico, Otilia Bisbal-Pardo, Víctor Arenas-García, Alfonso Cabello-Úbeda, Miguel Egido-Murciano, Roberto Pedrero-Tomé (Madrid, Spain) PDF
Clinical management considerations – Adolescents
P190: Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA study in Cameroon
Nadine Fainguem Nguendjoung, Yagai Bouba, Rachel Kamgaing, Davy Hyacinthe Gouissi Anguechia, Aude Christelle Ka’e, Alex Durand Nka, Annie Nga Motaze, Francis Ateba, Alice Ketchaji, Nelly Kamgaing, Michel Carlos Tommo Tchouake, Rogers Ajeh, Calixte Ida Penda, Vittorio Colizzi, Paul Koki Ndombo, Alexis Ndjolo, Carlo-Federico Perno, Samuel Martin Sosso, Joseph Fokam (Yaounde, Cameroon)
P191: Baseline HIV genotyping in Saudi Arabian population, a multicentre, cross-sectional study
Roaa Alosaimi, Batool Ali, Moayad Alqurashi, Reem Almutairi, Ali Alsaeed, Meqbel Alshelawi, Abdullah Alkhalaf, Abdullah Alsubaie, Layla Faqih (Jeddah, Saudi Arabia) PDF
P192: Increasing understanding in transitioning into adult care for adolescents living with HIV: effect of online education on physician knowledge and confidence
Shanthi Voorn, Alessia Piazza, Gill Adair, Ann Chahroudi, Caroline J. Foster (London, UK) PDF
Clinical management considerations – Paediatrics
P193: HIV drug resistance among children and adolescents with viraemia in Lesotho and Tanzania: a secondary analysis of the GIVE MOVE trial
Christof Manuel Schönenberger, Kathrin Haenggi, Isaac Kaumbuthu Ringera, Ezekiel Luoga, Moniek Bresser, Buoang Mothobi, Kuena Mokhele, David Sando, Brenda Simba, Mamello Molatelle, Lineo Thahane, Dorcas Mnzava, Robert Ndege, Mosa Molapo Hlasoa, Buntshi Paulin Kayembe, Josephine Muhairwe, Tracy Renée Glass, Thomas Klimkait, Maja Weisser, Niklaus Daniel Labhardt, Nadine Tschumi, Jennifer Anne Brown (Basel, Switzerland) PDF
P194: Tolerability of lopinavir versus dolutegravir for children and adolescents living with HIV (LoDoCA): a prospective cohort study in Lesotho, southern Africa
Jacob Blankenberger, Akash Devendra, Meenakshi Bakaya, Tristan Lee, Teresa Steffy, Thithili Makhesi, Jennifer Belus, Nadine Tschumi, Nthuseng Marake-Raleie, Reto Huber, Frédérique Chammartin, Niklaus Labhardt, Jennifer Brown (Basel, Switzerland)
P195: Structured caregiver literacy sessions: a path to 100% viral load suppression among children living with HIV, Matata Hospital experience, Homa Bay County
Brian Boit (Homabay, Kenya)
Clinical management considerations – Drug-drug interactions
P198: The geriatric assessment and frequency of polypharmacy and severe drug-drug interactions in older adults with HIV in a tertiary care centre in Mexico City
Su Jung Choi, Alvaro López-Íñiguez, Yanink Caro-Vega, Virgilio Hernández-Ruiz, José Alberto Ávila-Funes, Rocio Angelica Sánchez-Morales, Melissa Guerrero-Tobias, Karen Aranza Marañón-Solorio, Juan Carlos Franco-Rodríguez, Brenda Eloisa Crabtree-Ramírez, Juan Sierra-Madero (Mexico City, Mexico)
P199: Safety and efficacy of pharmacotherapy containing the second-generation integrase inhibitors (INSTIs) and chemotherapy drugs in AIDS-related diffuse large B-cell lymphoma: a single-centre retrospective analysis
Jing Yang (Chengdu, China)
P201: Tracing the evolution of polypharmacy and drug-drug interactions in people living with HIV
Victoria Lopez Delhoulle, Li-Cécile Destordeur, Nathalie Maes, Karine Fombellida, Majdouline El Moussaoui, Gilles Darcis (Liège, Belgium) PDF
P202: Concomitant administration of long-acting cabotegravir/rilpivirine and intramuscular antibiotics for the treatment of sexually transmitted infections: no evidence of pharmacodynamic interference
Roberto Rossotti, Nicholas Brian Bana, Francesco Peracchi, Gabriele Cavazza, Elisa Di Gennaro, Chiara Baiguera, Alessandro Raimondi, Marco Merli, Carlotta Rogati, Federico D’Amico, Maria Cristina Moioli, Massimo Puoti (Milan, Italy) PDF
P203: A study on pharmacist antiretroviral stewardship in relation to drug interaction checking within the Genitourinary Medicine and Infectious Diseases (GUIDe) outpatient clinic in St James’s Hospital
Arlene Heekin, Teresa M. Barbosa, Miriam Moriarty, Miriam Coghlan, Colm Bergin (Dublin, Ireland) PDF Audio
Cure/post-treatment control
P205: Characterising HIV-1 elite controllers within the Italian ICONA cohort: implications for HIV functional cure
Francesca Ceccherini-Silberstein, Luna Colagrossi, Alessandro Tavelli, Omar El Khalili, Stefano Rusconi, Giuseppe Lapadula, Antonella Cingolani, Alessandra Vergori, Andrea Calcagno, Sergio Lo Caputo, Antonella Castagna, Alessandro Cozzi-Lepri, Giulia Carla Marchetti, Carlo-Federico Perno, Antonella d’Arminio Monforte (Rome, Italy) PDF
P206: Absence of viral rebound without antiretrovirals after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation: a new case of a potential cure of HIV?
Olivia Zaegel-Faucher, Céline Boschi, Samir Benkouiten, Hélène Laroche, Maëva Dos Santos, Anne Motte, Faezeh Izadifar-Legrand, Daniel Olive, Philippe Colson, Sylvie Bregigeon-Ronot (Marseille, France) PDF
P207: Characteristics and management of patients with low level viraemia (LLV) in Greece: a multicentre retrospective study
Lydia Leonidou, Giota Lourida, Konstantinos Protopapas, Chralambos Moschopoulos, Dimitrios Zoulas, Charisis Totsikas, Dimitrios Basoulis, Elpida Mastrogianni, Apostolos Beloukas, Maria Lagadinou, Markos Marangos, Vasileios Papastamopoulos, Antonios Papadopoulos, Mina Psichogiou (Patras, Greece)
P208: VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models
Michael Keegan, Margaret Gartland, Saikat Chakraborty, Judah Abberbock, Wilson Chen, Paul Wannamaker, Peter Leone, Jan Losos, Richard Dunham (London, UK) PDF Audio
P209: Perceptions of healthcare professionals, civil society, pharmaceutical industry and decision-makers around the role of Latin America and the Caribbean in seeking HIV cure
Natalia Laufer, Gaston Devisich, Gabriela Turk, Fernando Valiente-Echeverria, María Figueroa, Pedro Cahn, Omar Sued, Claudia Cortes, Brenda Crabtree-Ramírez, Isabel Cassetti (Buenos Aires, Argentina) PDF
P210: Insights to a cure: unique controller phenotypes in the Rotterdam HIV-2 cohort
Kathryn Hensley, Rob Gruters, Els van Nood, Mariana de Mendonça Melo, Ronald Overmars, Alicja Gorska, Casper Rokx, Cynthia Lungu, David van de Vijver, Thibault Mesplède, Jeroen van Kampen (Rotterdam, Netherlands) PDF
P211: Safety and immunogenicity of GS-1966+GS-1144 vaccines in virally suppressed adults living with HIV-1: a phase Ib, randomized, placebo-controlled study
Constance A. Benson, Cynthia Brinson, Moti N. Ramgopal, Anthony M. Mills, Edwin DeJesus, Karin Jooss, Pamela M. Odorizzi, Susie S. Y. Huang, Keith Flower, Yongwu Shao, Christiaan R. de Vries, Devi SenGupta (Foster City, CA, USA)
P212: Peptide-induced apoptosis of latently infected cells and reduction of the HIV reservoir in people living with HIV: preliminary results of a clinical trial
Ricardo Sobhie Diaz, Mauro Schechter, Daniel Elbirt, Esmira Naftali, Juliana Maricato, Marcella Vassao de Almeida Baptista, Juliana Galinskas, Danilo Dias, Alessandra Bassini, Nadya Lisovoder, James Hunter, Eynat Finkelshtein (Sao Paulo, Brazil) PDF
P213: Perceptions of analytical treatment interruption among people with HIV using antiretroviral therapy in the United States
Karine Dube, Sorana Segal-Maurer, Martha Gauthier, Martin Duracinsky, Kathy Vong, Harlow Sharp, Blaise Cureg, Imani Weeks, Kwanza Price, James Jarrett, Caroline Burk (Foster City, CA, USA) PDF
P214: Relationship between the functionality of HIV-specific T-cell response and HIV persistence:
relevance in the context of cure strategies
Lucia Baquero, Leonel Cruces, Sofia Stover, Alejandra Urioste, Alejandro Czernikier, Tomás Langer, Yanina Ghiglione, Gabriela Turk, Natalia Laufer (Buenos Aires, Argentina) PDF Video
Opportunistic infections and AIDS defining cancers
P215: Comparative effectiveness of BIC/FTC/TAF versus other ART regimens in patients with AIDS-defining conditions: virological suppression and immunological recovery at 24 and 48 weeks in the ACTUAS II study
Ignacio Perez Valero, Diana Corona Mata, Angela Camacho Espejo, Marina Gallo, Inmaculada Jarrin, Antonio Rivero Juarez, Alejandro G. García-Ruiz de Morales, Chiara Fanciulli, Luz Martín Carbonero, Sonia Calzado Isbert, Cristina Hernández Gutiérrez, Víctor Asensi, Antonio Rivero Roman (Cordoba, Spain) PDF
P216: Trends in HIV diagnoses and AIDS-defining conditions, Croatia 2009-2023
Josip Begovac, Ivana Benković, Sime Zekan, Nina Vrsaljko, Marija Santini (Zagreb, Croatia) PDF
P217: Residual disease challenge efforts to achieving successful cervical dysplasia treatment in women living with HIV in Botswana
Patricia Rantshabeng, Nambumba Loide Amundaba, Moses Rugemalila, Alemayehu Eshetu, Lynnette Kyokunda (Gaborone, Botswana) PDF
P218: Evaluation of the new AltoStar® HHV-7/-8 PCR Kit 1.5 RUO for the quantitative detection of HHV-8 DNA in plasma, whole blood and PBMCs
Martin Obermeier, Özlem Yildirim, David Mwangi, Malik Prentice, Stefan Breuer, Pascal Migaud, Robert Ehret (Berlin, Germany) PDF
P219: High proportion of circulating CD8+CD28- T cells predicts inferior prognosis in AIDS-related non-Hodgkin lymphoma
Juanjuan Chen, Jie Peng, Zixin Kang, Xin Tao, Shuting Wu (Guangzhou, China) PDF
P220: Pneumocystis pneumonia cases in HIV and non-HIV individuals in a peripheral hospital in Portugal: an 11-year experience
Gustavo Lemos Correia, Francisco Soares Laranjeira, Raquel Tavares, Filipa de Oliveira Nunes, Liliana Alves, Rita Sérvio, Paulo Rodrigues (Loures, Portugal) PDF
P221: Breaking the age and immunological limits: enhancing cancer treatment in people living with HIV with anti-PD-(L)1 therapies
Sibo Li, Wenjing Wang, Yue Yuan, Xiaojie Huang, Hao Wu (Beijing, China)
P222: Cryptosporidiosis in HIV/AIDS patients in Belgrade, Serbia: a single-centre study
Ivana Gmizic, Zorica Dakic, Ivan Rajkovic, Jovana Ranin, Borko Pavlica, Snezana Jovanovic, Jovan Ranin (Belgrade, Serbia) PDF
Clinical pharmacology
P223: Effectiveness of a dual therapy based on DTG/3TC on reduction of the viral reservoir, immune recovery and immune activation compared with a triple antiretroviral therapy based on DTG/TAF/FTC in patients with HIV infection without prior treatment
Abraham Saborido-Alconchel, María Trujillo-Rodríguez, Ana Serna-Gallego, Esperanza Muñoz-Muela, Inmaculada Rivas-Jeremias, Ana Álvarez-Ríos, Nuria Espinosa, Cristina Roca, Marta Herrero, César Sotomayor, Alicia Gutierrez-Valencia, Luis Fernando López-Cortés (Seville, Spain) PDF
P224: Pharmacokinetics of oral islatravir (ISL) plus lenacapavir (LEN) given once weekly in an open-label, active-controlled, phase II study of virologically suppressed people with HIV-1
Diane Longo, Gillian Gillespie, Michelle Pham, Stephanie Klopfer, Haeyoung Zhang, Ramesh Palaparthy, Angela S. Y. Liu, Randolph P. Matthews, Cyril Llamoso, Elizabeth G. Rhee, Aubrey Stoch, Dhananjay D. Marathe, Ryan Vargo (Rahway, NJ, USA) PDF
P225: Assessing the effects of age and polypharmacy on dolutegravir exposure in plasma and the central nervous system
Brian Ho, Miao Zhang, Scott Letendre, Ronald Ellis, Donald Franklin, Leah Rubin, Anne Bang, Gene Morse, Donald Mager, Nicholas Smith, Qing Ma (Buffalo, NY, USA)
P226: Association of adenosine triphosphate-binding cassette transporter G2 (ABCG2) genetic polymorphisms with subjective symptoms and weight gain by bictegravir administration in Japanese HIV-1-infected patients
Hiroki Yagura, Dai Watanabe, Takao Nakauchi, Kazuyuki Hirota, Takuro Matsumura, Takashi Ueji, Yasuharu Nishida, Munehiro Yoshino, Tomoko Uehira, Takuma Shirasaka (Osaka, Japan) PDF
Community-based treatment and prevention initiatives, including primary care screening
P227: Is undiagnosed HIV prevalence among MSM in London changing in the era of combination prevention? Data from the Gay Men’s Sexual Health Survey, a serial cross-sectional community sample
Flavien Coukan, Dana Ogaz, Gary Murphy, Hamish Mohammed, John Saunders, Fiona Burns (London, UK) PDF
P228: Immunovirological outcomes in people living with HIV between immigrant and non-immigrant at the Hospital Clinic of Barcelona (2010-2023)
Alexy Inciarte, Elizabeth Zamora-Clemente, Leire Berrocal, Berta Torres, Lorena De La Mora, Elisa de Lazzari, Montserrat Laguno, Maria Martinez-Rebollar, Ana González-Cordón, Ivan Chivite, Alberto Foncillas, Julia Calvo, Abiu Sempere, Juan Ambrosioni, Jose Luis Blanco-Arevalo, Jose M. Miró, Esteban Martinez-Chamorro, Josep Mallolas (Barcelona, Spain) PDF
P229: The war in Ukraine exacerbates the problem of late HIV detection
Tetiana Koval, Liliia Buria, Olena Marchenko, Olga Stetsenko, Tetiana Bajda (Poltava, Ukraine) PDF
P230: HIV in a cohort of female sex workers: far to meet 95:95:95 goals
María Macarena Sandoval, Mona Loutfy, Virginia Zalazar, Agustín Nava, Nadir F. Cardozo, Mariela Ceschel, Marcela Romero, Georgina Orellano, Carina Cesar, Carolina Pérez, Ana Gun, María Inés Figueroa, Adriana Durán, Inés Arístegui, Zulma Ortiz, Pedro Cahn, Sharon Walmsley, Valeria Fink (Buenos Aires, Argentina) PDF
P231: Pilot implementation of HIV self-testing in Ghana: analysis of the community-based demand generation approach
Ernest Amoabeng Ortsin, Jonathan Tetteh-Kwao Teye, Richard Socrate Adzesi, Kwadwo Koduah Owusu, Anthony Ashinyo, Stephen Ayisi Addo (Accra, Ghana)
P232: Factors contributing to pneumococcal, COVID-19 and influenza vaccine uptake among people living with HIV in Belgium: a retrospective study
Li-Cécile Destordeur, Victoria Lopez Delhoulle, Iraklis Papadopoulos, Karine Fombellida, Majdouline El Moussaoui, Gilles Darcis (Liège, Belgium) PDF
P233: Reporting standard compliance in publications of mobile application interventions for antiretroviral therapy adherence among people living with HIV
Abdulhammed Babatunde, Dimeji Olawuyi, Folashade Olajuwon, Shamsudeen Olatokun, Olutola Awosiku, Isaac Ekundayo (Ibadan, Nigeria)
P234: Implementing effective infectious disease screening in syringe service programmes
Heather Henderson, Jason Wilson, Bernice McCoy (Tampa, FL, USA)
P235: Influence of community-based oral “PrEP” refill model on adherence and retention among adolescents in Homa Bay County, Kenya
Electrine Osewe, Seth Kagia (Nairobi, Kenya)
P236: The impact of migratory patterns in a HIV care clinic of a tertiary hospital in Portugal
Joana Marinho Silva, Gonçalo Cruz, Cristina Valente (Coimbra, Portugal) PDF
P237: Use of human-centred design to co-develop a digital platform and evaluate its use to drive uptake of HIV pre-exposure prophylaxis (PrEP) among Nigerian youths in Lagos, Nigeria through a pilot intervention study
Yusuf Babatunde, Oluwakorede Adedeji, Ibrahim Abdulmumin (Kigali, Nigeria) PDF
P238: Missed opportunities of HIV diagnosis and its clinical repercussions on the Portuguese population: a cohort study
João Lourinho, Maria João Miguel, Frederico Gonçalves, Francisco Vale, Cláudia Franco, Nuno Marques (Almada, Portugal)
P239: Characterization of chemsex in PrEP users in four hospitals of Buenos Aires, Argentina
Maria Belen Zorz, Isabel Pastor, Mariana Angelica Kundro, Guillermo Alberto Viloria, Marina Alonso Serena, Federico Cardozo, Diego Cecchini, Jose Barletta, Iael Altclas, Marcelo Horacio Losso (Ciudad Autonoma de Buenos Aires, Argentina) PDF
P240: Long-acting therapy (LA): what Italian PLWHIV think about it
Sandro Mattioli, Leonardo Del Negro, Salvio Cecere (Bologna, Italy) PDF
P241: HIV and STI checkpoint screening in Kiel: 4 years of screening in a medium-sized regional centre
Lutz Ohrtmann (Kiel, Germany)
P242: Check-Mobil: counselling, testing and case management for vulnerable groups in Schleswig-Holstein, Germany
Konstantin Kandlen, Louisa Glaum, Sylvia Brillat, Angela Stelling, Ursula Hansen, Hildegard Welbers, sarah Salvador (Kiel, Germany) PDF
P243: Retaining adolescents with HIV/AIDS in care through targeted youth camps in Kisumu, Kenya
Annabel Kokeyo, Geri DelaRosa Brooks, Nancy Yienya, Benard Samba, Margret Mburu, Mary A. Guze, Jayne Lewis Kulzer, Michelle Moghadassi (Kisumu, Kenya)
Public health strategies including of policy options
P244: Nationality and referral sources of people with HIV seeking first consultations: a 13-year retrospective cohort study at the Hospital Clinic of Barcelona
Elizabeth Zamora-Clemente, Alexy Inciarte, Leire Berrocal, Berta Torres, Lorena De La Mora, Elisa de Lazzari, Montserrat Laguno, Maria Martinez-Rebollar, Ana González-Cordón, Ivan Chivite, Alberto Foncillas, Julia Calvo, Abiu Sempere, Juan Ambrosioni, Jose Luis Blanco-Arevalo, Jose M. Miró, Esteban Martinez-Chamorro, Josep Mallolas (Barcelona, Spain) PDF Audio
P245: Modena and Emilia-Romagna HIV surveillance: the application of ECDC HIV Modelling Tool
Marianna Menozzi, Adriana Cervo, Gianluca Cuomo, Margherita Digaetano, Beatrice Fontana, Alessandra Soffritti, Erika massimiliani, Vanni Borghi, Giovanni Guaraldi, Cristina Mussini (Modena, Italy) PDF
P246: CHildren Of the Cohort study (CHOC): the unseen population behind people living with HIV
Clara Merlin, José Damas, Olivier Nawej Tshikung, Noémie Wagner, Anna Hachfeld, Andrea Duppenthaler, Marcel Stoeckle, Malte Kohns, Irene A. Abela, Paolo Paioni, Luigia Elzi, Lisa Kottanattu, Patrick Schmid, Christian R. Kahlert, Katharina Kusejko, Pierre Alex Crisinel, Pascal Pellegrino, Matthias Cavassini, Katharine Darling (Lausanne, Switzerland) PDF
P247: Assisted partner notification for HIV: a qualitative study in Cape Town, South Africa
Shehani Perera, Alison Swartz, Jennifer Nyawira Githaiga (Cape Town, South Africa) PDF
P248: The benefits of free counselling and testing for HIV and STIs in Zurich, Switzerland: a cross-sectional study
Leonie Arns-Glaser, Andrea Farnham, Jan S. Fehr, Benjamin Hampel (Zurich, Switzerland)
P249: Understanding knowledge and attitudes regarding HIV amongst secondary care healthcare professionals in the United Kingdom: a national survey
Moses Shongwe, Michael Brady, Daniel Clutterbuck, Alyscia Curtis, Hilary Curtis, Nadi Gupta, Claire Hutton, Neal Marshall, Jane Nicholls, Hajra Okhai, Joel Paparello, Melissa Perry, Laura Waters, John White (London, UK) PDF
P250: Migration as a driver of change in characteristics of new referrals of people living with HIV in a tertiary hospital in Lisbon, Portugal
Pedro Leal, Constança Antunes, Margarida Almeida, João Borralho, Sofia Rocha, Ana Cláudia Miranda, Teresa Baptista, Kamal Mansinho (Lisboa, Portugal) PDF
P251: Transmitted drug resistance to antiretroviral therapy: interim analysis from a cross-sectional study including 11 healthcare centres in Chile
Maria Elena Ceballos, Cinthya Ruiz-Tagle, Felipe Castañeda, Marcela Ferrés, Angélica Domínguez de Landa, Manuel Espinoza, María Elvira Balcells (Santiago, Chile) PDF
P253: CHildren Of the Cohort study (CHOC): exploring parenting desire among people living with HIV
in Switzerland
Clara Merlin, José Damas, Olivier Nawej Tshikung, Noémie Wagner, Anna Hachfeld, Andrea Duppenthaler, Marcel Stoeckle, Malte Kohns, Irene A. Abela, Paolo Paioni, Luigia Elzi, Lisa Kottanattu, Patrick Schmid, Christian R. Kahlert, Katharina Kusejko, Pierre Alex Crisinel, Pascal Pellegrino, Matthias Cavassini, Katharine Darling (Lausanne, Switzerland) PDF
P254: Public knowledge, views, perceptions and attitudes towards HIV and people living with HIV
in Switzerland: results of a national survey
Thomas Grabinger, Marlon Gattiker, David Haerry, Corinna Oberle, Dominique Braun, Katharine Darling (Zug, Switzerland) PDF
P255: Once HIV knowledge is addressed: HIV-stigma from the perspective of healthcare professionals working in HIV facilities in French-speaking Switzerland
Clara Le Saux, Ingrid Gilles, David Jackson-Perry, Ellen Cart-Richter, Olivier Nawej Tshikung, Katharine Darling (Lausanne, Switzerland) PDF
P256: Undetectable = Untransmittable, are we transmitting the message correctly?
Natalia Laufer, Lorena Abusamra, Leonel Cruces, María José Rolón, Alicia Sisto (Buenos Aires, Argentina) PDF
P257: Opt-out blood borne virus (BBV) testing in emergency medicine (EM) in a low prevalence setting
Daniela Brawley, Pauline Dundas, Lisa Allerton, Noha El Sakka, Gareth Patton (Aberdeen, UK) PDF
P258: U=U: awareness and impact on the quality of life in PWH; experience of a Greek HIV unit
Konstantinos Protopapas, Onisiphoros Neophytou, Charalampos D. Moschopoulos, Georgios Zampetas, Konstantinos Thomas, Dimitra Kavatha, Antonios Papadopoulos (Athens, Greece) PDF
P259: Persistent HIV related stigma in Germany across different origins: findings from university hospital study
Anna Koval, Maher Almahfoud, Hanna Matthews, Angela Buchholz, Sanna Higgen, Anja-Dorothee Huefner, Friederike Theresia Marie Hunstig, Luise Roggelin, Sabine Jordan, Stefan Schmiedel, Olaf Degen (Hamburg, Germany)
P260: Use of participatory approach in developing interventions for HIV prevention in Africa
Abdulhammed Babatunde, Yusuf Babatunde, Oluwakorede Adedeji (Ibadan, Nigeria)
P261: The attitudes towards providing care for people living with HIV among healthcare workers in Poland
Filip Fijołek, Martyna Cholewik, Carlo Bienkowski, Justyna D. Kowalska, Agata Skrzat-Klapaczynska (Warsaw, Poland) PDF
P262: Outcomes, public health responses, lessons learned and current status of the HIV outbreak
(10 year overview)
Becky Metcalfe, Sharon Hutchinson, Andrew McAuley, Daniel Carter, Julie Craik, S. Erica Peters (Glasgow, UK) PDF
P263: Estimating return on investment (ROI) with increased utilisation of HIV pre-exposure prophylaxis (PrEP) among key populations in France
Turgay Ayer, Emir Gursel, Mert Edali, Claire Idelovici-Marchal, Elias Benabadji, James Jarrett, Dylan Mezzio (Foster City, CA, USA) PDF
Cost and cost-effectiveness
P264: Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada
Adenike Adelakun, Michael Dolph, Emily Matthews, Alan Oglesby, Kelly Campbell, Ashley Davis, Janine Xu, Isabelle Hardy, Natalya Danchenko, Sarah-Jane Anderson (Mississauga, Canada) PDF Audio
P265: The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men at high risk
of HIV acquisition in eight Latin American countries
Jamile Ballivian, Leandro Pastori, Elena Lazo, Carolina Moreno, Camila Volij, Velenn Penini, Adrian Santoro, Santiago Esteban, Adolfo Rubinstein, Federico Augustovski, Andres Pichon-Riviere, Sebastian Garcia-Marti (Buenos Aires, Argentina) PDF
P266: Economic estimation of the management of neuropsychiatric events in people with HIV in real life
Juan Tiraboschi, Alvaro Mena-de-Cea, Jesus Troya Garcia, Antonio Castro, Pilar Cabrera, Neus Vidal-Vilar (Barcelona, Spain) PDF
Models of care: evaluation of ARV delivery and coverage
P268: Is continuum of care for HIV and hepatitis C possible during war migration: Five Times Ninety project
Justyna Kowalska, Olena Samsonova, Sergii Antoniak, Bartłomiej Matlosz (Warsaw, Poland)
P269: Sociodemographic factors influencing retention in care among people with HIV immigrants
at Hospital Clinic of Barcelona: a 12-year retrospective cohort study
Alexy Inciarte, Elizabeth Zamora-Clemente, Leire Berrocal, Berta Torres, Lorena De La Mora,Elisa De Lazarri, Montserrat Laguno, Maria Martinez-Rebollar, Ana Gonzalez Cordón, Alberto Foncillas, Ivan Chivite, Julia Calvo, Abiu Sempere, Juan Ambrosioni, Jose Luis Blanco-Arevalo, Jose M. Miró, Esteban Martinez-Chamorro, Josep Mallolas (Barcelona, Spain) PDF Audio
P270: Model of remote HIV linkage to care at the AIDS centre: utilising the EECA region as an example
Dmitrii Korenev, Kirill Barskiy (Moscow, Russian Federation) PDF
P271: Free HIV drugs as a key tool against the HIV pandemic: a systematic review
Benoît Lemire, Melissa Doutre, Marie-Pier Godin, Iliya Dmitriev, Amy Bergeron, Lucie Blais, Ana Paula Bruno Pena Gralle (Montreal, Canada) PDF
P272: Changes in the ART coverage and viral suppression from 2020 to 2022 in Kyiv, Ukraine
Olga Fursa, Joanne Reekie, Wendy Bannister, Larysa Hetman, Alina Kryshchuk, Olena Starychenko, Nana Hrytsaiuk, Inna Khodus, Alla Nyzhnyk, Viktoriia Rakhuba, Maryna Kovalevska, Olena Valdenmaiier, Jens Lundgren, Lars Peters (Copenhagen, Denmark) PDF
P273: The impact of migratory patterns in HIV profile: an analysis of genotype and resistance mutations of the migrant population in a tertiary hospital
Gonçalo Pereira Cruz, Joana Marinho Silva, Cristina Valente (Coimbra, Portugal) PDF
P274: BIC/TAF/FTC in treatment-naive PLWH: the experience of a centre
Constança Antunes, Sofia Rocha, Andreia Meseiro, Margarida Almeida, Marta Almeida, Dina Mendes, Ana Cláudia Miranda, Teresa Baptista, Kamal Mansinho (Lisbon, Portugal) PDF
P275: Successful and practical model of care targeting disengaged people living with HIV: the Oak Clinic experience at Russells Hall Hospital in Dudley, United Kingdom
Adel Shoukry (Dudley, UK)
P276: A patient survey to explore why patients ‘Did Not Attend’ in a large inner-city HIV service
Wai Lin Htun, Anna Garner (Manchester, UK) PDF
Co-morbidities and complications of disease and/or treatment – Ageing and frailty
P277: Comparison of four frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study)
Clotilde Allavena, Diane Abulizi, Hubert Blain, Valérie Adriantsoanirina, Sophie Abgrall, Marina Karmochkine, Christine Katlama, Miresta Previlon, André Cabie, Fabrice Bonnet, Laurence Meyer, Alain Makinson (Nantes, France) PDF Audio
P278: Acceptability and feasibility of digital assessment of falls risk, frailty and mobility impairment
using wearable sensors in PLWH as part of HIV care
Claire Norcross, Inayat Khan, Tom Levett, Birgit Barbini, Lucy Campbell, Leigh McQueen, Elizabeth Hamlyn, Jaime Vera (Brighton, UK) PDF
P279: Antiretroviral therapy, comorbidities and concomitant medication in people with HIV aged over 75 years in one centre in London, UK
Maithili Varadarajan, Kareemah Kannike, Ankita Sahni, Yaser Al- Shakarchi, Nadia Naous, Modest Nwanbila, Nicolo Girometti, Timothy Tong, Marta Boffito (London, UK) PDF
P280: The virtual care experience for persons living with HIV during the COVID pandemic
Sharon Walmsley, Marina Klein, Majid Nabipoor, Valerie Martel-Laferriere, Mona Loutfy, Curtis Cooper, Marie-Louise Vachon, Bryan Boyachuk, Pamela Aldebes (Toronto, Canada) PDF
P281: Association between low skeletal muscle mass and lung function decline in people with HIV
Katrine Munk, Moisés Alberto Suarez-Zdunek, Rikke Krabek, Louise Bering, Casper Simonsen, Klaus Fuglsang Kofoed, Andreas Fuchs, Lars Valeur Køber, Thomas Benfield, Sisse Rye Ostrowski, Andreas Dehlbæk Knudsen, Susanne Dam Nielsen (Copenhagen, Denmark)
P282: Evaluation of T-cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study
Matteo Vassallo, Michel Ticchioni, David Chirio, Ami Sadou, Eric Cua, Carole Ceppi, Sara Ferrando, Alissya Naqvi, Bernard Prouvost-Keller, Sommani Mangin-Ratana, Leslie Ameil, Maeva Godemert, Michel Carles, Jacques Durant (Cannes, France) PDF
Co-morbidities and complications of disease and/or treatment – Cardiovascular/metabolic including weight gain
P283: Risk of hypertension in treatment-naïve people with HIV (PWH) in the US receiving integrase strand inhibitors (INSTIs) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or tenofovir alafenamide (TAF) versus non-TAF-based regimens: pooled analysis of blood pressure data from five clinical trials
Priscilla Y. Hsue, Laura Waters, Chloe Orkin, Juan Manuel Tiraboschi, Anchalee Avihingsanon, Andrea Marongiu, Andrew Whiteman, Yuan Tian, Carrie M Nielson, Keith Aizen, Cal Cohen, Jason T. Hindman, Jürgen K. Rockstroh (San Francisco, CA, USA) PDF
P284: Two-fold increased risk of cardiovascular events in people with multidrug-resistant HIV: data from the PRESTIGIO registry
Tommaso Clemente, Sara Diotallevi, Davide Minisci, Antonio Di Biagio, Riccardo Lolatto, Letizia Attala, Giovanni Cenderello, Alessia Siribelli, Camilla Muccini, Sergio Lo Caputo, Marcello Tavio, Rebecka Papaioannu Borjesson, Andrea Giacomelli, Antonella Castagna, Vincenzo Spagnuolo (Milan, Italy) PDF
P285: Incident hypertension with antiretroviral therapy: real-world evidence from the OPERA cohort
Philip C. Lackey, Laurence Brunet, Jennifer S. Fusco, Gerald Pierone Jr, Michael B. Wohlfeiler, Douglas T. Dieterich, Cassidy E. Henegar, Vani Vannappagari, Bryn Jones, Annemiek de Ruiter, Gregory Fusco (Durham, NC, USA) PDF
P286: Evaluation of cardiovascular disease amongst adults with perinatally acquired HIV
Merle Henderson, Vibeke Klastrup, Salwa Ahmad, Jessica Glenn, Sara Ayres, Hana Jadayel, Paula Seery, Caroline Foster, Sarah Fidler (London, UK) PDF
P287: Evaluation of changes in Systematic Coronary Risk Evaluation 2 (SCORE2) in experienced people with HIV switching to DOR/3TC/TDF: real-world data from DOROTEA multicentre cohort
Valentina Iannone, Alberto Borghetti, Andrea Giacomelli, Davide Moschese, Filippo Lagi, Massimiliano Fabbiani, Andrea Rabbione, Giuseppe Formica, Francesca Lombardi, Chiara Papalini, Andrea Tommasi, Daniela Francisci, Andrea De Vito, Giordano Madeddu, Maria Vittoria Cossu, Simona Di Giambenedetto, Arturo Ciccullo (Rome, Italy) PDF
P288: Cabotegravir and rilpivirine reduce the risk of developing metabolic syndrome
Martina Ranzenigo, Sara Diotallevi, Riccardo Lolatto, Hamid Hasson, Silvia Nozza, Flavia Badalucco Ciotta, Maria del Carmen Garcia Martearena, Ilaria Mainardi, Gaia Catalano, Antonella Castagna, Camilla Muccini (Milano, Italy) PDF
P289: Incidence of metabolic syndrome in people with HIV in Italy who started ART since 2008: data from the ICONA cohort
Elena Bruzzesi, Alessandro Tavelli, Romina Salpini, Anna Carraro, Marta Camici, Chiara Papalini, Gregorio Recchia, Carmen Rita Santoro, Maria Vittoria Cossu, Alessandra Guida, Annalisa Mondi, Giulia Marchetti, Giovanni Guaraldi, Antonella d’Arminio Monforte, Silvia Nozza (Milan, Italy)
P290: The effect of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) on whole-body insulin sensitivity in volunteers without HIV
Joseph Heskin, Roya Movahedi, Sujin Kang, Ruth Byrne, Krestine Elecito, Perrine Gridel, Paola Marchesani, Graeme Moyle, Ana Milinkovic, Marta Boffito (London, UK) PDF
P293: Cytomegalovirus antibodies and coronary artery disease in people with HIV
Moises Alberto Suarez-Zdunek, Andreas Dehlbæk Knudsen, Andreas Fuchs, Nikolai Søren Kirkby, Thomas Benfield, Jan Gerstoft, Marius Trøseid, Lars Valeur Køber, Klaus Fuglsang Kofoed, Susanne Dam Nielsen (Copenhagen, Denmark) PDF
P294: N6-methyladenine DNA and ABCA1 methylation association with coronary atherosclerosis
in asymptomatic people with HIV with low-intermediate cardiovascular risk
Jose I Bernardino, Regina Dalmau, Diego Rodriguez-Torres, Gabriel Saiz-Medrano, María Fernandez-Velilla, Inmaculada Pinilla, Javier Rodriguez-Centeno, Andres Esteban-Cantos, Tatiana Mata, Carmen Ramos, Berta Rodes, Miriam Estebanez (Madrid, Spain) PDF
P295: Metabolic syndrome among people living with HIV (PLWH) in a specialist HIV clinic in London
Yomna Gharib, Irfaan Maan, Manik Kohli, Andrew Copas, Emmi Suonpera, Fowsiya Nur, Anya MacLaren, James Mason, Laura Waters, Richard Gilson, Sarah Pet, Alejandro Arenas-Pinto (London, UK) PDF
P296: Prevalence of metabolic syndrome in people living with HIV and its relationship with fatty liver
and cardiovascular risk
Adrian Rodriguez, Ignasi Merino, Aroa Villoslada, Patricia Sorni, Marta Molero, Araceli Serrano, Andrea Salom, Francisco Homar, Antoni Payeras (Palma, Spain) PDF
P297: Cardiovascular disease risk according to SCORE2 and the potential need for cholesterol and blood pressure lowering therapy in persons with HIV without established cardiovascular disease, Croatia
Josip Begovac, Vanja Romih Pintar, Sanja Belak Škugor, Ivana Benković, Ivana Javorić, Sime Zekan (Zagreb, Croatia) PDF
P298: Online education yields significant gains in physicians’ knowledge of the complexities of cardiometabolic disease in people living with HIV
Shanthi Voorn, Alessia Piazza, Gill Adair, Patrick Mallon, Carlos Diego Malvestutto, Esteban Martinez (London, UK) PDF
P299: Carotid intima-media thickness, dyslipidaemia, high cardiovascular risk and real-life prescriptions of statins among people living with HIV enrolled in Archi Prevaleat cohort
Benedetto Maurizio Celesia, Salvatore Martini, Elena Delfina Ricci, Sergio Ferrara, Laura Galli, Addolorata Masiello, Alessandra Tartaglia, Michele Salvatore Paternò Raddusa, Rosa Basile, Antonella Castagna, Paolo Maggi (Catania, Italy)
P300: Association between high sensitivity troponin and NT-pro brain natriuretic peptide and peripheral arterial disease in people living with HIV
Thomas Holtveg, Anne Marie Reimer Jensen, Ask Bock, Moises Alberto Suarez-Zdunek, Andreas Dehlbæk Knudsen, Børge Nordestgaard, Shoaib Afzal, Thomas Lars Benfield, Sisse Rye Ostrowski, Tor Biering-Sørensen, Ruth Frikke-Schmidt, Susanne Dam Nielsen (Copenhagen, Denmark) PDF
P301: Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of weight Gain in naïve people living with HIV of Asian OrigiN (DRAGON study)
Jang-Pin Chen, Tsung-Chia Chen, Wen-Hsin Hsih, Mao-Song Tsai, Chia-Jui Yang, Shu-Hsing Cheng, Yi-Chun Lin, Ping Ma, Qingxia Zhao, Meiyin Zou, Yi-Wen Wu, Miao-Hui Huang, Wang-Huei Sheng, Chien-Yu Cheng (Taoyuan, Taiwan) PDF
P302: Evaluating the cardiovascular risk and the achievement of target levels in low-density lipoprotein cholesterol in PLWH: insights from the DUALIS study
Florian Voit, Sven Breitschwerdt, Annamaria Balogh, Helen Bidner, Silvia Egert-Schwender, Christoph Boesecke, Laura Wagner, Eva Wolf, Christoph Spinner (Munich, Germany) PDF
P303: Prevalence and cardiovascular risk assessment in HIV patients: comparison between SCORE2 and REGICOR scales
Estefanía Díaz Martín, Inês Cachapa Viera, Sonia Calzado Isbert, María Del Carmen Navarro Saez, Marc Pedrosa Aragón, Marta Navarro Vilasaró (Barcelona, Spain) PDF Audio
P304: A novel approach to weight loss: bringing I-SatPro into the HIV clinic
Eleanor Hamlyn, Jorge Ferreira, Sarah Edwards, Tricia Tan, Saira Hameed, Fiona Burns (London, UK) PDF
P306: Immune and metabolic profile in people living with HIV initiating emtricitabine/tenofovir alafenamide/bictegravir
Nicola Squillace, Elena Delfina Ricci, Paolo Maggi, Lucia Taramasso, Barbara Menzaghi, Giuseppe Vittorio De Socio, Eleonora Sarchi, Stefania Piconi, Giovanni Francesco Pellicanò, Giordano Madeddu, Alessandra Bandera, Salvatore Martini, Benedetto Maurizio Celesia, Giancarlo Orofino, Sergio Ferrara, Emanuele Pontali, Maria Aurora Carleo, Elena Salomoni, Giovanni Cenderello, Antonio Cascio, Goffredo Angioni, Katia Falasca, Olivia Bargiacchi, Antonio Di Biagio, Paolo Bonfanti (Monza, Italy) PDF
Co-morbidities and complications of disease and/or treatment – Malignancies: non-AIDS defining
P307: Outcomes after the most common cancers in people with HIV
Alisa Timiryasova, Lauren Greenberg, Pere Domingo, Philip E Tarr, Alexander Egle, Charlotte Martin, Cristina Mussini, Ferdinand Wit, Antonella Cingolani, Jörg Janne Vehreschild, Antonella Castagna, Kathy Petoumenos, Caroline Sabin, Wafaa El-Sadr, Fabrice Bonnet, Jens Lundgren, Martina Botanelli, Sean Hosein, Christina Carlander, Alain Amstutz, Katharina Grabmeier-Pfistershammer, Harmony Garges, Andrea Marongiu, Lital A Young, Lars Peters, Lene Ryom (Copenhagen, Denmark) PDF
P308: High burden of non-AIDS defining malignancies among adults with HIV in Thailand, 1996-2023
Teton Avihingsanon, Rin Indarodom, Pathaitorn Damtham, Farsai Chiewbangyang, Win Min Han, Jiratchaya Sophonphan, Haymar Su Lwin, Anchalee Avihingsanon, Napa Parinyanitikul (Bangkok, Thailand) PDF
P309: Screening for anal precancerous lesion and cancer in Japan
Naokatsu Ando, Daisuke Mizushima, Misao Takano, Hiroshi Kitamura, Daisuke Shiojiri, Seitaro Abe, Akira Kawashima, Ryo Kuwata, Takato Nakamoto, Takahiro Aoki, Shinichi Oka, Hiroyuki Gatanaga (Tokyo, Japan) PDF
P310: Effectiveness of trichloroacetic acid for the treatment of HPV-related anal high-grade squamous intraepithelial lesions
Jaime Vega-Costa, Ana Silva-Klug, Mónica Sánchez, Loris Trenti, Maria Saumoy (Hospitalet de Llobregat, Spain)
P311: Higher prevalence of high-risk HPV genotypes and lesions in the youngest: do IANS guidelines align with clinical findings?
Elena Bruzzesi, Sara Diotallevi, Federica Gandini, Riccardo Lolatto, Massimo Cernuschi, Caterina Candela, Angelo Roberto Raccagni, Flavia Passini, Andrea Marco Tamburini, Roberto Burioni, Antonella Castagna, Silvia Nozza (Milan, Italy)
P312: Cancers in people living with HIV: an observational study in the cohort of Modena over 27 years
Federica Prandini, Marianna Menozzi, Federica Casari, Deborah Lusetti, Beatrice Fontana, Martina Ricciardetto, Elena Ghidoni, Filippo Calandra, Elena Martini, Giovanni Guaraldi, Cristina Mussini (Modena, Italy) PDF
P314: High-resolution anoscopy referral rates when adopting IANS consensus guidelines for anal cancer screening in men who have sex with men living with HIV
Christof Stingone, Maria Benevolo, Francesca Rollo, Eugenia Giuliani, Massimo Giuliani, Paolo Giorgi Rossi, Laura Gianserra, Mauro Zaccarelli, Alessandra Latini, Maria Gabriella Donà (Rome, Italy)
P315: Shifting patterns and outcomes of malignancies in people living with HIV: a 10-year retrospective study
Susana Ramos Oliveira, Mafalda Teixeira Costa, Cristina Soeiro, Clara Bacelar, Clara Batista, Sara Vale Araújo, Mário Guimarães, Constança Azeredo, Frederico Duarte, Sónia Duarte Rocha, Fábio Reis, Eduarda Ruiz Pena, Maria João Gonçalves, Ricardo Correia de Abreu, Sofia Jordão (Senhora da Hora, Portugal) PDF
Co-morbidities and complications of disease and/or treatment – Neurological
P316: Cognitive performance and patient-reported outcomes in older people with HIV in the GEPPO cohort
Federica Barrera, Andrea Calcagno, Andrea Tommasi, Lavinia Patetta, Jovana Milic, Alessandra Coin, Chiara Mussi, Stefano Calza, Benedetto Maurizio Celesia, Samuele Gardin, Domenico Azzolino, Elisa Lenotti, Micol Ferrara, Benedetta Fioretti, Giordano Madeddu, Giancarlo Orofino, Emanuele Focà, Giovanni Guaraldi (Turin, Italy)
P317: The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study
Saumitro Deb, Jessica Doctor, Jaime Vera, Frank Post, Jasmini Alagaratnam, Patrick W. G. Mallon, Jane Anderson, Laura Waters, Nicki Doyle, Fiona Burns, Memory Sachikonye, Alan Winston, Caroline Sabin (London, UK) PDF
P318: Brain functional connectivity changes over 18 months in persons with acute and chronic HIV infection
Charalampos D. Moschopoulos, Evangelia Stanitsa, Efstratios Karavasilis, Konstantinos Protopapas, Dimitra Kavatha, Antonios Papadopoulos, Georgios Velonakis, Sokratis G. Papageorgiou, Anastasia Antoniadou (Athens, Greece) PDF
Co-morbidities and complications of disease and/or treatment – Renal
P319: Long-term change of renal function among people with HIV who received TAF-containing ART
Guan-Jhou Chen, Hsin-Yun Sun, Szu-Min Hsieh, Wang-Hui Sheng, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung (Taoyuan, Taiwan) PDF
P320: Reduction in estimated glomerular filtration rate (eGFR) observed with doravirine (DOR) is caused by inhibition of organic cation transporter 2 (OCT2)
Yang Li, Xiaoyan Chu, Rosa I. Sanchez, Russ P. Carstens, Mary L. Pisculli, Stephanie Klopfer, Zhi Jin Xu, Rima Lahoulou, Rebeca M. Plank (Rahway, NJ, USA) PDF
P322: Kidney transplantation in liver-transplanted HIV-positive recipients with end-stage renal disease: two case reports
Daniela Malano Barletta, Nuria Esforzado, Pablo Ruiz, Frederic Cofan, Montserrat Laguno, David Cucchiari, Alejandro Forner, Hugo López, Mireia Musquera, Asunción Moreno, Antonio Rimola, Fritz Diekmann, José María Miró (Barcelona, Spain)
P323: Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study
Sébastien Gallien, Lambert Assoumou, Jacques Dantal, Anne Hulin, Aida Benalycherif, Raida Ben Rayana, Yasmine Tobbal, Marie Matignon, Giovanna Melica, Clotilde Allavena, Thomas Stehle (Créteil, France) PDF
Co-morbidities and complications of disease and/or treatment – Mental health disorders
P324: Resilience among people with HIV: results from the UK Positive Voices 2022 survey
Colette Smith, Janey Sewell, Alex Sparrowhawk, Annegret Pelchen-Matthews, Fumiyo Nakagawa, Fiona Wilson, Tracey Fong, Hannah Kitt, Carole Kelly, Meaghan Kall, Veronique Martin, Adamma Aghaizu, Alison Rodger, Fiona Lampe (London, UK) PDF
P325: Mental health in people with HIV (PWH): patient-reported outcomes in the DUALIS study
Eva Wolf, Annamaria Balogh, Florian Voit, Judith Laufenberg, Christoph Boesecke, Christine Koegl, Christoph D Spinner, Andreas Dinkel, on behalf of the DUALIS Study Group (Munich, Germany) PDF
P326: Anxiety and depression in people living with HIV/AIDS (PLHIV) and their impact on fatigue and health-related quality of life (HRQOL)
Pulin Kumar Gupta, Akhil Goyal, Atul Anand (New Delhi, India) PDF
P327: No association of cART and HIV-related parameters with health-related quality of life (HR-QoL) of PLWH: insights from a multidimensional screening
Stella Capodieci, Mauro Zaccarelli, Alessandra Latini, Christof Stingone, Laura Gianserra, Maria Gabriella Donà, Eugenia Giuliani, Valentina Cafaro, Massimo Giuliani (Rome, Italy) PDF
P328: Predictors of mortality among tuberculosis patients with mental health disorders: a retrospective study at a national referral mental hospital in Uganda
Isaiah Aryatuha, Patrick Kazooba, Gertrude Namale, Emmanuel Sendaula,Josephine Kaleebi (Kampala, Uganda) PDF
P329: Mental health service access barriers and facilitators among people living with HIV: a qualitative study in Georgia
Esma Imerlishvili, Maia Kajaia, Mariam Pashalishvili, Eka Chkhonia, Tamar Zurashvili, Ramesh Raghavan, Mamuka Djibuti (Tbilisi, Georgia) PDF
Co-morbidities and complications of disease and/or treatment – Other
P330: Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) + lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies
Dainielle Fox, Gary Blick, Thibault Mesplède, Gustavo Verdier, Mónica Calderón, Chris M. Parry, Richard Grove, Emilio Letang, Julie Priest, Bryn Jones (Durham, NC, USA) PDF
P331: Use of lipid-lowering drugs, even when associated with polypharmacy, reduces risk of hospitalisation in PWH >50 years
Jovana Milic, Alessandra Carobbio, Antonia Pugliese, Pierluigi De Cosmo, Lorenzo Federici, Federico Motta, Filippo Calandra Buonaura, Matteo Mantovani, Francesca Gandolfi, Chiara Mussi, Cristina Mussini, Giovanni Guaraldi (Modena, Italy) PDF
P332: Penile vascular status in young men living with HIV experiencing erectile dysfunction: a comparative cross-sectional study
Giorgio Tiecco, Marco Di Gregorio, Cosimo Colangelo, Andrea Delbarba, Matteo Riva, Carlo Cappelli, Emanuele Focà, Francesco Castelli, Eugenia Quiros-Roldan (Brescia, Italy) PDF
P333: The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study over a 3-5 year period
Luxsena Sukumaran, Alan Winston, Patrick W. G. Mallon, Frank A. Post, Memory Sachikonye, Marta Boffito, Nicki Doyle, Jaime Vera, Jane Anderson, Fiona M. Burns, Caroline A. Sabin (London, UK)
P334: Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia
Erich Tusch, Lene Ryom, Christian Hoffmann, Olaf Degen, Robert Zangerle, Huldrych Günthard, Ferdinand Wit, Cristina Mussini, Antonella Castagna, Charlotte Martin, Andrea Giacomelli, Jörg Janne Vehreschild, Josip Begovac, Vani Vannappagari, Jim Rooney, Lital Young, Joan Tallada, Justyna Kowalska, Elmar Wallner, Katharina Kusejko, Nadine Jaschinski, Jens Lundgren, Lars Peters, Joanne Reekie (Copenhagen, Denmark)
P335: Stigma in older people with HIV: disclosure concerns and self-image do not improve over time
in older AGEhIV cohort study participants
Kevin Moody, Myrthe L. Verburgh, Ferdinant W. N. M. Wit, Sarah Stutterheim, Maarten F. Schim van der Loeff, Peter Reiss, Pythia T. Nieuwkerk, Marc van der Valk (Amsterdam, Netherlands) PDF
P336: Prevalence of unmet need for support managing long-term conditions among people with HIV
Adamma Aghaizu, Hannah Kitt, Carole Kelly, Alison Brown, Alex Sparrowhawk, Fiona Wilson, Judith Zhou, Meaghan Kall, Alison Rodger, Janey Sewell, Annegret Pelchen-Matthews, Colette Smith, Valerie Delpech, Veronique Martin, Clare Humphreys (London, UK)
P337: Profile of suicide cases in the Spanish CoRIS cohort between 2004-2022
Julián Olalla, Alfonso Del Arco, Melchor Riera, Joaquim Peraire, Enrique Bernal, Javier De la Torre, Antonia Castillo-Navarro, Lorena Martínez-Fernández, Javier Pérez-Stachowski, Santiago Moreno (Marbella, Spain) PDF
P338: The clinical utility of targeted screening for liver fibrosis/cirrhosis among people living with HIV (PLWH)
Izuchukwu Ezeh, Amy Hardy, Martin Prince, Vincent Lee (Manchester, UK) PDF Audio
P339: Patient-reported outcome measures among people with HIV on antiretroviral therapy in Kunming, China
Yongmei Jin, Jun Liu, Bo Tian, Chongxi Li (Kunming, China)
P340: Virological failure and patterns of resistance-associated mutations in previously untreated HIV-positive participants in the RESINA cohort
Smaranda Gliga, Michael Böhm, Nadine Lübke, Alexander Killer, Falk Hüttig, Claudia Müller, Eva Heger, Joachim Büch, Gerd Fätkenheuer, Clara Lehmann, Mark Oette, Martin Hower, Heribert Knechten, Niels Schübel, Stefan Esser, Stephan Schneeweiß, Nazifa Qurishi, Katja Römer, Rolf Kaiser, Tom Luedde, Björn Jensen (Düsseldorf, Germany) PDF
P341: Online education yields significant gains in physicians’ knowledge of the physical implications of stigma in people living with HIV
Shanthi Voorn, Alessia Piazza, Gill Adair, Chloe Orkin, Maile Young Karris (London, UK) PDF
P342: Identification of quality-of-life alterations among people living with HIV in Romania: ROCTAVE self-administered questionnaire
Oana Sandulescu, Victor Daniel Miron, Irina Magdalena Dumitru, Manuela Arbune, Anca Streinu-Cercel (Bucharest, Romania)
P343: Anti-retroviral regimen change and its predictors among people living with HIV in Hawassa University Comprehensive Specialized Hospital, southern Ethiopia, retrospective cohort study
Endrias Makos Woldesemayat, Wonago Petros, Jaime Vera (Hawassa, Ethiopia)
P344: The impact of cART on the intracellular antioxidant capacity in peripheral blood mononuclear cells
of people living with HIV
Radoslava Emilova, Yana Todorova, Reneta Dimitrova, Victor Manolov, Nina Yancheva, Milena Aleksova, Damian Vangelov, Maria Nikolova (Sofia, Bulgaria) PDF
P345: Unmasked immune reconstitution syndrome diagnoses among people living with HIV admitted in a low-resource hospital, Homabay, Kenya 2021-2022
Edward Corneleous Odhiambo Okal, Thaddeus Owiti, James Wagude, Gordon Okomo (Homabay, Kenya)
People living with HIV and COVID-19: Outcomes
P346: Proteic and mRNA XBB.1.5 SARS-CoV-2 vaccines elicit a close neutralising response against JN.1 in PWH
Alessandra Vergori, Giulia Matusali, Eleonora Cimini, Alessandro Cozzi-Lepri, Federico Cecilia, Davide Mariotti, Francesca Colavita, Simona Gili, Flavia Cristofanelli, Marisa Fusto, Valentina Mazzotta, Jessica Paulicelli, Roberta Gagliardini, Enrico Girardi, Fabrizio Maggi, Andrea Antinori (Rome, Italy)
P347: No changing incidence of type 2 diabetes in PWH before and after the first wave of the COVID-19 pandemic
Alessandra Vergori, Alessandro Tavelli, Sara De Benedittis, Nicola Squillace, Lucia Taramasso, Roberto Rossotti, Eugenia Quiros Roldan, Andrea Santoro, Andrea Calcagno, Simone Lanini, Giuseppe Lapadula, Giovanni Guaraldi, Antonella Castagna, Andrea Antinori, Alessandro Cozzi-Lepri (London, UK)
P348: Don’t turn that patient away, they must be seen.” A qualitative exploration of the views of London HIV clinical service providers on HIV care engagement challenges (the SHIELD study)
Rageshri Dhairyawan, Shiraaz Sidat, Rebecca Mbewe, Silvia Petretti, Jane Anderson, Vanessa Apea, Sara Paparini, Chloe Orkin (London, UK) PDF
People living with HIV and mpox virus
P350: Mpox clade II in France in 2023-2024: an endemic situation?
Mayda Rahi, Sebastien Fouere, Marie Gilbert, Antoine Bachelard, Fabien Taieb, Baptiste Sellem, Florian Herms, Charles Cazanave, Gentiane Monsel, Yazdan Yazdanpanah, Nathan Peiffer-Smadja, Jade Ghosn (Paris, France) PDF
P351: One-year review of mpox in Hong Kong
Laura Pui Yee To, Ching See Leung, Yau Chung Choi, Alicia Wing Tung Lau, Sophia Sharon Lamb, Daphne Pui Ling Lau, Thomas Shiu Hong Chik, Ki Wai Heather To, Bonnie Chun Kwan Wong, Jacky Man Chun Chan, Owen Tak Yin Tsang (Hong Kong Special Administrative Region, China) PDF
P352: Exploring synergistic social media effects for people with HIV during the mpox epidemic: the evolution of the HIV case manager into a podcaster
Chung-Ching Shih, Chin-Fang Huang, Wei-Ming Chen (Taipei, Taiwan) PDF
P353: Exploring mpox vaccination uptake and tolerability among individuals living with HIV: a single-centre study in an infectious disease unit in Italy
Samuele Gaggioli, Giuseppe Formica, Valentina Petrini, Alessandra Russo Krauss, Costanza Fiorelli, Paola Corsi, Alessandro Di Felice, Costanza Malcontenti, Michele Trotta, Emanuela Francalanci, Giulia Modi, Francesca Costa, Seble Tekle Kiros, Lorenzo Zammarchi, Alessandro Bartoloni, Filippo Lagi (Firenze, Italy) PDF
People living with HIV and sexually transmitted diseases
P355: Knowledge, attitudes and behaviours in relation to doxycycline post-exposure prophylaxis (dPEP) use amongst attendees and healthcare workers at a large sexual health and HIV service in Ireland
Amy Keane, Fiona Lyons, Diego Caixeta, Colette Smith, Jean-Michel Molina, Giovanni Villa (Dublin, Ireland) PDF
P356: Incidence and clearance of high-grade anal squamous intraepithelial lesions in men who have sex with men living with HIV
Maria Saumoy, Ana Silva-Klug, Jaime Vega, Monica Sánchez, Joao Carmezin, Miguel Angel Pavon, Laia Alemany, Núria Baixeres, Loris Trenti, Sónia Paytubi (Hospitalet de Llobregat, Spain) PDF
P357: Characterisation of specific T-cell responses to a three-doses nonavalent HPV vaccine schedule
in PLWH on ART
Eeva Tortellini, Mariasilvia Guardiani, Federica Dominelli, Carmen Falvino, Anna Carraro, Sara Corazza, Sara Giovanna De Maria, Silvia Garattini, Blerta Kertusha, Lorenzo Ansaldo, Maria Antonella Zingaropoli, Fabio Mengoni, Cristina Giambi, Cosmo Del Borgo, Raffaella Marocco, Miriam Lichtner (Rome, Italy)
P358: Study on the prevalence and incidence of dysplasia and HPV infection of the oropharyngeal, cervical and anal mucosa (oropharyngeal) of people with HIV
Carmen Hidalgo Tenorio, Inmaculada Calle-Gómez, Raquel Moya-Mejias, Mohamed Omar, Javier Lopez Hidalgo, Javier Rodriguez Granges, Carmen Garcia Martinez (Granada, Spain) PDF
P359: Exploring interest in long-acting antiretroviral injections: perspectives of people living with HIV in Egypt and Saudi Arabia
Salma M. A. Mansour, Roaa Alosaimi, Heba Fahmy, Ahmed Cordie, Rahma Mohammed, Batool Ali, Ganna Essam Elnahas, Amany A. Salem, Ibrahim Ali Kabbash (Jeddah, Saudi Arabia) PDF
P360: Treatment of Mycoplasma genitalium and detection of macrolide resistance mutations (23S rRNA) in PHIV and HIV-negative individuals
Elena Suanzes-Martín, María Muñoz-Algarra, Sara De la Fuente-Moral, Ilduara Pintos-Ramos, Natalia Vicente-López, Alberto Díaz de Santiago (Madrid, Spain) PDF
P361: Antimicrobial resistance pattern in Neisseria gonorrhoeae isolates from men having sex with men (MSM): results from the first prospective cohort in Poland
Bartosz Szetela, Beata Maczynska, Konrad Starzynski, Daria Zareba, Danuta Ruranska-Smutnicka, Anna Sacewicz, Paulina Szuba, Martyna Biala (Wroclaw, Poland) PDF
P362: Syphilis incidence among HIV-infected MSM and IDUs is as high before and after achieving U=U in Japan
Hauka Uemura, Daisuke Mizushima, Naokatsu Ando, Takato Nakamoto, Takahiro Aoki, Katsuji Teruya, Hiroyuki Gatanaga (Tokyo, Japan)
P363: Epidemiological study of the prevalence of STIs and HIV among men who have sex with men in the Russian Federation
Dmitrii Korenev, Kirill Barskiy (Moscow, Russian Federation) PDF
P364: Neisseria gonorrhoeae (NG) infection in MSM: clinical and microbiological characteristics –
culture is essential but provides limited assistance
Cristina Gómez-Ayerbe, María López-Jódar, Salvador Martin-Cortes, Marina Villalobos, Isabel Ascensión Pérez-Hernández, María Victoria García-López, Rosario Palacios, Jesús Santos (Málaga, Spain) PDF
P366: Malignant syphilis as the initial manifestation of HIV: a case report
Filippo Calandra Buonaura, Marco Visicaro, Antonella Santoro, Cristina Mussini (Modena, Italy) PDF
P367: Syphilis profile in individuals on post-exposure prophylaxis with doxycycline (Doxy PEP)
Rosario Palacios, María López-Jódar, Salvador Martin-Cortés, Andrea Prolo, Isabel Ascensión Pérez-Hernández, Isabel Viciana, Cristina Gómez-Ayerbe, Jesús Santos (Málaga, Spain) PDF
P368: Acceptability and real-life experience of doxyPEP in MSM at a combined HIV/PrEP clinic in a Southeast Asian university hospital
Dariusz Olszyna, Eon Tat Gan, Tiane Le, Sophia Archuleta (Singapore, Singapore) PDF
People living with HIV and tuberculosis
P369: Long-term efficacy of tuberculosis preventive treatment in people living with HIV: a single centre prospective cohort study
Napon Hiranburana, Haymar Su Lwin, Jiratchaya Sophonphan, Win Min Han, Chuleeporn Khongpetch, Anchalee Avihingsanon (Bangkok, Thailand)
P370: Impact of injection drug use on tuberculosis outcomes in people with HIV: a nationwide cohort study
Naila Bugyi-Bozo, Josep M Llibre, Iben Ørsted, Nina Breinholt Stærke, Johanna Åhsberg, Gitte Kronborg, Steffen Leth, Lars Haukali Omland, Niels Obel, Line Dahlerup Rasmussen, Isik Somuncu Johansen, Raquel Martin-Iguacel (Odense, Denmark) PDF
P371: Evaluating tuberculosis prevalence in key populations with advanced HIV diseases in Nigeria
Mark Akhigbe, Roger Abang, Abiye Kalaiwo, Paul Umoh (Uyo, Nigeria)
People living with HIV and viral hepatitis
P373: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve people with both HIV-1 and hepatitis B: 3-year outcomes from ALLIANCE
Anchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, Chien-Ching Hung, Sasisopin Kiertiburanakul, Man-Po Lee, Khuanchai Supparatpinyo, Sharline Madera, Hongyuan Wang, Jason Hindman, Taisheng Li (Bangkok, Thailand) PDF
P374: Long-term outcomes of people living with HCV/HIV with advanced hepatic fibrosis treated with direct-acting antivirals: a retrospective study
João Matos, Inês Caetano, Flavia Faria, Francisco Novela, António Ludgero Vasconcelos, Josefina Méndez (Porto, Portugal) PDF
P376: Acute/recent infections and reinfections by HCV in MSM with and without HIV in the region of Madrid (ATHENS study)
Pablo Ryan, Juan Berenguer, Luis Ramos, Mar Vera, Leire Pérez-Latorre, Ignacio De los Santos, Adriana Pinto, Santos Del Campo, Eva Orviz, Beatriz Alvarez, José Sanz, Pilar Ruiz-Seco, Rafael Torres, Beatriz Brazal, Beatriz López-Centeno, José M. Bellón, Luz Martín-Carbonero, Juan González-García (Madrid, Spain) PDF
P377: HIV/HBV coinfection in Portugal today: data from a multicentric approach
Ruben Carvalho, Ana Martins, João Matos, Vanda Castro, Joana Martinez, António Ferreira, Catarina Esteves, Ana Parente, Jorge Velez, Josefina Mendez, Cristina Valente (Coimbra, Portugal) PDF
P378: HCV cure with direct-acting antivirals in HIV/HCV coinfected patients belonging to key populations
Cristiana Oprea, Irina Ianache, Cristiana Costescu, Sebastian Piscu, Sorina Vasile, Luminita Ene, Roxana Radoi, Ionut Popa (Bucharest, Romania) PDF
P379: “What we wanted was what we needed” – collaborative community advocacy for inclusive clinical trials in emerging hepatitis C research: lessons from the EATG Sitges model
Rocco Pignata, Ian Hodgson, Giorgio Barbareschi, Apostolos Kalogiannis, Fiona Greenhalgh, Brian West, Sean Hosein, Alain Volny-Anne, Luis Mendão, Memory Sachikonye (Brussels, Belgium) PDF
P380: HIV/HCV: barriers to treatment in the era of direct acting antivirals in a low-middle income country
Raquel Zhumi, Cruz Molina Neizly, Falak Adriana, Alicia Sisto, Maria Rolon, Natalia Laufer (Buenos Aires, Argentina) PDF
P381: The era of DAAs: assessing the patients’ characteristics, clinical impact, and emergence of comorbidities in HIV/HCV-coinfected versus HIV-infected individuals
Beatriz Álvarez-Álvarez, Laura Prieto-Pérez, Alberto de la Cuadra-Grande, Miguel Ángel Casado, Alfonso Cabello Úbeda, Aws W. Al-Hayani, Irene Carrillo Acosta, Ignacio Mahillo-Fernández, Miguel Górgolas Hernández-Mora, José M. Benito, Norma Rallón (Madrid, Spain) PDF
P382: Predictors of hepatitis C treatment failure in people living with HIV
Alan Sinuhe Medina Valle, Elizabeth Mendoza Portillo, Humberto Gudiño Solorio (Mexico City, Mexico) PDF
People living with HIV and other diseases
P383: Preliminary results of a pilot study to evaluate the usefulness of using patient-reported outcomes (PROs) in the follow-up of patients living with HIV
Sara de la Fuente Moral, María Pilar Corrales Rodríguez, Ana Belén Hernández López, Carlos Folguera Olías, Belén Menchén Viso, Miriam Redondo, Victoria Ayala Vargas, María Sainz Guerra, Alberto Díaz de Santiago (Madrid, Spain)
P384: Preferences for a psychosocial intervention based on health and wellbeing coaching, for people living with HIV in a secondary care setting in England, Wales and Scotland: a discrete choice experiment
Janey Sewell, Meaghan Kall, Adamma Aghaizu, Alec Miners, Alex Sparrowhawk, Jane Holder, Farai Mukazi, Alison Rodger, Fiona Lampe, Valentina Cambiano (London, UK) PDF
P386: Inflammatory biomarkers decay after first-line antiretroviral treatment initiation with dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide. What puts the fire out faster?
Analuz Fernandez, Sofia Scevola, Raul Rigo Bonin, Maria Saumoy, Arkaitz Imaz, Daniel Podzamczer,
Juan Manuel Tiraboschi (Barcelona, Spain) PDF
P387: Assessing the utility of a simple respiratory symptom screening tool in an outpatient population of people with HIV
Andrew Read, Rob F. Miller, Fiona M. Burns, Jane Akodu, Sarah Edwards, James Brown, Marc Lipman, Tristan J. Barber (London, UK) PDF
P388: Additional vaccination in PLWH: adherence in a central hospital in Lisbon
António Moreno-Marques, Fátima Gonçalves, Zélia Rodrigues Sobral, Fábio Cota-Medeiros (Lisboa, Portugal) PDF